

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



B6

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>7</sup> : C12N 15/12, C07K 14/47, C12N 15/63, C07K 16/18, A61K 38/17, C12Q 1/68		A1	(11) International Publication Number: <b>WO 00/15794</b> (43) International Publication Date: 23 March 2000 (23.03.00)
(21) International Application Number: PCT/US99/20988 (22) International Filing Date: 9 September 1999 (09.09.99) (30) Priority Data: 09/151,611 11 September 1998 (11.09.98) US (63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Application US 09/151,611 (CIP) Filed on 11 September 1998 (11.09.98) (71) Applicant (for all designated States except US): INCYTE PHARMACEUTICALS, INC. [US/US]; 3174 Porter Drive, Palo Alto, CA 94304 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): YUE, Henry [US/US]; 826 Lois Avenue, Sunnyvale, CA 94087 (US). AU-YOUNG, Janice [US/US]; 1419 Kains Avenue, Mountain View, CA 94702 (US). PATTERSON, Chandra [US/US]; 490 Sherwood Way #1, Menlo Park, CA 94025 (US). (74) Agents: BILLINGS, Lucy, J. et al.; Incyte Pharmaceuticals, Inc., 3174 Porter Drive, Palo Alto, CA 94304 (US).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
(54) Title: HUMAN CELL JUNCTION PDZ PROTEIN			
(57) Abstract  The invention provides a human cell junction PDZ protein (CJPDZ) and polynucleotides which identify and encode CJPDZ. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with expression of CJPDZ.			

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

## HUMAN CELL JUNCTION PDZ PROTEIN

### TECHNICAL FIELD

5           This invention relates to nucleic acid and amino acid sequences of a cell junction PDZ protein and to the use of these sequences in the diagnosis, treatment, and prevention of cancer, neurological disorders, and developmental disorders.

### BACKGROUND OF THE INVENTION

10           Cells communicate with and respond to their environment by receiving and processing extracellular signals. These signals take the form of growth factors, hormones, cytokines, and peptides which bind to and activate specific plasma membrane receptors. The activated receptors trigger intracellular signal transduction pathways which culminate in a wide range of cellular responses affecting gene expression, protein secretion, cell cycle progression, and cell  
15           differentiation. Initial events in signal transduction require the proximity of intracellular signaling proteins to the cytosolic domains of activated plasma membrane receptors. These intracellular membrane-associated signaling proteins couple the activated receptor to downstream second messenger systems and play a key role in the regulation and coordination of complex, multiprotein signal transduction pathways. Recently, a conserved protein domain called the PDZ domain has  
20           been identified in various membrane-associated signaling proteins. This domain has been implicated in receptor and ion channel clustering and in the targeting of multiprotein signaling complexes to specialized functional regions of the cytosolic face of the plasma membrane. (For review of PDZ domain-containing proteins, see Ponting, C.P. et al. (1997) Bioessays 19:469-479.)

          PDZ domains were named for three proteins in which this domain was initially  
25           discovered. These proteins include PSD-95 (postsynaptic density 95), Dlg (Drosophila lethal(1)discs large-1), and ZO-1 (zonula occludens-1). These proteins play important roles in neuronal synaptic transmission, tumor suppression, and cell junction formation, respectively. Since the discovery of these proteins, over sixty additional PDZ-containing proteins have been identified in diverse prokaryotic and eukaryotic organisms. A large proportion of PDZ domains  
30           are found in the eukaryotic MAGUK (membrane-associated guanylate kinase) protein family, members of which bind to the intracellular domains of receptors and channels. However, PDZ domains are also found in diverse membrane-localized proteins such as protein tyrosine phosphatases, serine/threonine kinases, G-protein cofactors, and synapse-associated proteins such as syntrophins and neuronal nitric oxide synthase (nNOS). Generally, about one to three PDZ

domains are found in a given protein, although up to nine PDZ domains have been identified in a single protein.

X-ray crystallography has shown that PDZ domains are generally compact globular structures containing about 80 to 100 amino acids which form six  $\beta$ -strands and two  $\alpha$ -helices.

5 PDZ domains tend to be rich in glycine residues which introduce turns in the polypeptide chain and promote compaction and stability of the folded polypeptide. In particular, a glycine-aspartic acid (GD) dipeptide and an asparagine residue which occurs six residues thereafter are highly conserved in nearly all PDZ domains and are important for domain structure. PDZ domains bind to a tripeptide motif containing valine and serine or threonine. Most ligands which bind PDZ  
10 domains contain this motif, although some ligands lack this motif or contain conservative substitutions therein.

Members of the MAGUK protein family play an important role in the clustering of neurotransmitter receptors and channels, and this clustering is essential for neuron function (Ponting, supra). In the presence of a neurotransmitter, the PDZ domains of PSD-95, PSD-93,  
15 SAP-97 (synapse-associated protein 97), SAP-102, and chapsyn 110 bind to the cytosolic C-termini of N-methyl-D-aspartate (NMDA) neurotransmitter receptors and Shaker-type potassium channels, causing them to cluster. In addition, interaction of the PDZ domain of PSD-95 with that of nNOS anchors the latter in proximity to the NMDA receptors.

In the nematode Caenorhabditis elegans, the PDZ-containing protein, LIN-7, is required  
20 during development for the specification of cells which give rise to the vulva (Simske, J.S. et al. (1996) Cell 85:195-204). These precursor cells form an epithelium in the sexually immature nematode. A diffusible epidermal growth factor (EGF)-like signal is secreted in the vicinity of the epithelium. Cells in sufficiently close proximity to the signal respond by activating an EGF-like receptor tyrosine kinase/Ras-mediated signal transduction pathway. Responding cells  
25 subsequently give rise to generations of progeny cells which differentiate to form the vulva. The EGF-like receptor (EGFR) is localized to epithelial cell junctions, and this localization is essential for signal transduction and vulva formation. The LIN-7 gene is required for EGFR localization and encodes a 297 amino acid protein (SEQ ID NO:3) which contains a PDZ domain from amino acid 199 to amino acid 280.

30 PDZ-containing proteins are likely involved in disorders associated with defective cell signaling (Ponting, supra). As discussed above, PDZ domains have been shown to play important roles in development, and in fact, the gene encoding the PDZ-containing protein, LIM kinase 1, is deleted in patients with Williams syndrome, a complex developmental disorder. PDZ-containing proteins have also been implicated in oncogenesis. For example, mutations in Drosophila Dlg

causes neoplastic transformation of epithelial cells, and N-terminally truncated forms of the PDZ-containing protein, Tiam 1, are highly tumorigenic in nude mice. In addition, mutations that block clustering of neuronal receptors and channels cause perinatal lethality in mice, suggesting that the clustering function of neuronal MAGUK proteins is critical.

- 5       The discovery of a new cell junction PDZ protein and the polynucleotides encoding it satisfies a need in the art by providing new compositions which are useful in the diagnosis, prevention, and treatment of cancer, neurological disorders, and developmental disorders.

### SUMMARY OF THE INVENTION

- 10       The invention is based on the discovery of a new human cell junction PDZ protein (CJPDZ), the polynucleotides encoding CJPDZ, and the use of these compositions for the diagnosis, treatment, or prevention of cancer, neurological disorders, and developmental disorders.

The invention features a substantially purified polypeptide comprising the amino acid sequence of SEQ ID NO:1 or a fragment of SEQ ID NO:1.

- 15       The invention further provides a substantially purified variant having at least 90% amino acid sequence identity to the amino acid sequence of SEQ ID NO:1 or a fragment of SEQ ID NO:1. The invention also provides an isolated and purified polynucleotide encoding the polypeptide comprising the amino acid sequence of SEQ ID NO:1 or a fragment of SEQ ID NO:1. The invention also includes an isolated and purified polynucleotide variant having at least 90%  
20       polynucleotide sequence identity to the polynucleotide encoding the polypeptide comprising the amino acid sequence of SEQ ID NO:1 or a fragment of SEQ ID NO:1.

- The invention further provides an isolated and purified polynucleotide which hybridizes under stringent conditions to the polynucleotide encoding the polypeptide comprising the amino acid sequence of SEQ ID NO:1 or a fragment of SEQ ID NO:1, as well as an isolated and purified  
25       polynucleotide having a sequence which is complementary to the polynucleotide encoding the polypeptide comprising the amino acid sequence of SEQ ID NO:1 or a fragment of SEQ ID NO:1.

- The invention also provides an isolated and purified polynucleotide comprising the polynucleotide sequence of SEQ ID NO:2 or a fragment of SEQ ID NO:2, and an isolated and purified polynucleotide variant having at least 90% polynucleotide sequence identity to the  
30       polynucleotide comprising the polynucleotide sequence of SEQ ID NO:2 or a fragment of SEQ ID NO:2. The invention also provides an isolated and purified polynucleotide having a sequence complementary to the polynucleotide comprising the polynucleotide sequence of SEQ ID NO:2 or a fragment of SEQ ID NO:2.

The invention also provides a method for detecting a polynucleotide in a sample

containing nucleic acids, the method comprising the steps of (a) hybridizing the complement of the polynucleotide sequence to at least one of the polynucleotides of the sample, thereby forming a hybridization complex; and (b) detecting the hybridization complex, wherein the presence of the hybridization complex correlates with the presence of a polynucleotide in the sample. In one  
5 aspect, the method further comprises amplifying the polynucleotide prior to hybridization.

The invention further provides an expression vector containing at least a fragment of the polynucleotide encoding the polypeptide comprising the sequence of SEQ ID NO:1 or a fragment of SEQ ID NO:1. In another aspect, the expression vector is contained within a host cell.

The invention also provides a method for producing a polypeptide, the method comprising  
10 the steps of: (a) culturing the host cell containing an expression vector containing at least a fragment of a polynucleotide under conditions suitable for the expression of the polypeptide; and (b) recovering the polypeptide from the host cell culture.

The invention also provides a pharmaceutical composition comprising a substantially purified polypeptide having the sequence of SEQ ID NO:1 or a fragment of SEQ ID NO:1 in  
15 conjunction with a suitable pharmaceutical carrier.

The invention further includes a purified antibody which binds to a polypeptide comprising the sequence of SEQ ID NO:1 or a fragment of SEQ ID NO:1, as well as a purified agonist and a purified antagonist of the polypeptide.

The invention also provides a method for treating or preventing a disorder associated with  
20 decreased expression or activity of CJPZ, the method comprising administering to a subject in need of such treatment an effective amount of a pharmaceutical composition comprising a substantially purified polypeptide having the amino acid sequence of SEQ ID NO:1 or a fragment of SEQ ID NO:1, in conjunction with a suitable pharmaceutical carrier.

The invention also provides a method for treating or preventing a disorder associated with  
25 increased expression or activity of CJPZ, the method comprising administering to a subject in need of such treatment an effective amount of an antagonist of the polypeptide having the amino acid sequence of SEQ ID NO:1 or a fragment of SEQ ID NO:1.

#### BRIEF DESCRIPTION OF THE FIGURES AND TABLE

30 Figures 1A, 1B, and 1C show the amino acid sequence (SEQ ID NO:1) and nucleic acid sequence (SEQ ID NO:2) of CJPZ. The alignment was produced using MACDNASIS PRO software (Hitachi Software Engineering, S. San Francisco CA).

Figure 2 shows the amino acid sequence alignment between residues 25 through 204 of CJPZ (1974337; SEQ ID NO:1) and residues 117 through 295 of *C. elegans* LIN-7 (GI 1685067;

SEQ ID NO:3), produced using the multisequence alignment program of LASERGENE software (DNASTAR, Madison WI).

Table 1 shows the programs, their descriptions, references, and threshold parameters used to analyze CJPZ.

5

## DESCRIPTION OF THE INVENTION

Before the present proteins, nucleotide sequences, and methods are described, it is understood that this invention is not limited to the particular machines, materials and methods described, as these may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the present invention which will be limited only by the appended claims.

It must be noted that as used herein and in the appended claims, the singular forms "a," "an," and "the" include plural reference unless the context clearly dictates otherwise. Thus, for example, a reference to "a host cell" includes a plurality of such host cells, and a reference to "an antibody" is a reference to one or more antibodies and equivalents thereof known to those skilled in the art, and so forth.

Unless defined otherwise, all technical and scientific terms used herein have the same meanings as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any machines, materials, and methods similar or equivalent to those described herein can be used to practice or test the present invention, the preferred machines, materials and methods are now described. All publications mentioned herein are cited for the purpose of describing and disclosing the cell lines, protocols, reagents and vectors which are reported in the publications and which might be used in connection with the invention. Nothing herein is to be construed as an admission that the invention is not entitled to antedate such disclosure by virtue of prior invention.

## DEFINITIONS

"CJPZ" refers to the amino acid sequences of substantially purified CJPZ obtained from any species, particularly a mammalian species, including bovine, ovine, porcine, murine, equine, and preferably the human species, from any source, whether natural, synthetic, semi-synthetic, or recombinant.

The term "agonist" refers to a molecule which, when bound to CJPZ, increases or prolongs the duration of the effect of CJPZ. Agonists may include proteins, nucleic acids, carbohydrates, or any other molecules which bind to and modulate the effect of CJPZ.

An "allelic variant" is an alternative form of the gene encoding CJPZ. Allelic variants



may result from at least one mutation in the nucleic acid sequence and may result in altered mRNAs or in polypeptides whose structure or function may or may not be altered. Any given natural or recombinant gene may have none, one, or many allelic forms. Common mutational changes which give rise to allelic variants are generally ascribed to natural deletions, additions, or substitutions of nucleotides. Each of these types of changes may occur alone, or in combination with the others, one or more times in a given sequence.

"Altered" nucleic acid sequences encoding CJPDPZ include those sequences with deletions, insertions, or substitutions of different nucleotides, resulting in a polypeptide the same as CJPDPZ or a polypeptide with at least one functional characteristic of CJPDPZ. Included within this definition are polymorphisms which may or may not be readily detectable using a particular oligonucleotide probe of the polynucleotide encoding CJPDPZ, and improper or unexpected hybridization to allelic variants, with a locus other than the normal chromosomal locus for the polynucleotide sequence encoding CJPDPZ. The encoded protein may also be "altered," and may contain deletions, insertions, or substitutions of amino acid residues which produce a silent change and result in a functionally equivalent CJPDPZ. Deliberate amino acid substitutions may be made on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic nature of the residues, as long as the biological or immunological activity of CJPDPZ is retained. For example, negatively charged amino acids may include aspartic acid and glutamic acid, positively charged amino acids may include lysine and arginine, and amino acids with uncharged polar head groups having similar hydrophilicity values may include leucine, isoleucine, and valine; glycine and alanine; asparagine and glutamine; serine and threonine; and phenylalanine and tyrosine.

The terms "amino acid" or "amino acid sequence" refer to an oligopeptide, peptide, polypeptide, or protein sequence, or a fragment of any of these, and to naturally occurring or synthetic molecules. In this context, "fragments," "immunogenic fragments," or "antigenic fragments" refer to fragments of CJPDPZ which are preferably at least 5 to about 15 amino acids in length, most preferably at least 14 amino acids, and which retain some biological activity or immunological activity of CJPDPZ. Where "amino acid sequence" is recited to refer to an amino acid sequence of a naturally occurring protein molecule, "amino acid sequence" and like terms are not meant to limit the amino acid sequence to the complete native amino acid sequence associated with the recited protein molecule.

"Amplification" relates to the production of additional copies of a nucleic acid sequence. Amplification is generally carried out using polymerase chain reaction (PCR) technologies well known in the art.

The term "antagonist" refers to a molecule which, when bound to CJPDZ, decreases the amount or the duration of the effect of the biological or immunological activity of CJPDZ. Antagonists may include proteins, nucleic acids, carbohydrates, antibodies, or any other molecules which decrease the effect of CJPDZ.

5       The term "antibody" refers to intact molecules as well as to fragments thereof, such as Fab, F(ab')<sub>2</sub>, and Fv fragments, which are capable of binding the epitopic determinant. Antibodies that bind CJPDZ polypeptides can be prepared using intact polypeptides or using fragments containing small peptides of interest as the immunizing antigen. The polypeptide or oligopeptide used to immunize an animal (e.g., a mouse, a rat, or a rabbit) can be derived from the translation of  
10 RNA, or synthesized chemically, and can be conjugated to a carrier protein if desired. Commonly used carriers that are chemically coupled to peptides include bovine serum albumin, thyroglobulin, and keyhole limpet hemocyanin (KLH). The coupled peptide is then used to immunize the animal.

      The term "antigenic determinant" refers to that fragment of a molecule (i.e., an epitope) that makes contact with a particular antibody. When a protein or a fragment of a protein is used to  
15 immunize a host animal, numerous regions of the protein may induce the production of antibodies which bind specifically to antigenic determinants (given regions or three-dimensional structures on the protein). An antigenic determinant may compete with the intact antigen (i.e., the immunogen used to elicit the immune response) for binding to an antibody.

      The term "antisense" refers to any composition containing a nucleic acid sequence which  
20 is complementary to the "sense" strand of a specific nucleic acid sequence. Antisense molecules may be produced by any method including synthesis or transcription. Once introduced into a cell, the complementary nucleotides combine with natural sequences produced by the cell to form duplexes and to block either transcription or translation. The designation "negative" can refer to the antisense strand, and the designation "positive" can refer to the sense strand.

25       The term "biologically active," refers to a protein having structural, regulatory, or biochemical functions of a naturally occurring molecule. Likewise, "immunologically active" refers to the capability of the natural, recombinant, or synthetic CJPDZ, or of any oligopeptide thereof, to induce a specific immune response in appropriate animals or cells and to bind with specific antibodies.

30       The terms "complementary" or "complementarity" refer to the natural binding of polynucleotides by base pairing. For example, the sequence "5' A-G-T 3'" bonds to the complementary sequence "3' T-C-A 5'." Complementarity between two single-stranded molecules may be "partial," such that only some of the nucleic acids bind, or it may be "complete," such that total complementarity exists between the single stranded molecules. The degree of

complementarity between nucleic acid strands has significant effects on the efficiency and strength of the hybridization between the nucleic acid strands. This is of particular importance in amplification reactions, which depend upon binding between nucleic acids strands, and in the design and use of peptide nucleic acid (PNA) molecules.

5       A "composition comprising a given polynucleotide sequence" or a "composition comprising a given amino acid sequence" refer broadly to any composition containing the given polynucleotide or amino acid sequence. The composition may comprise a dry formulation or an aqueous solution. Compositions comprising polynucleotide sequences encoding CJPDZ or fragments of CJPDZ may be employed as hybridization probes. The probes may be stored in  
10 freeze-dried form and may be associated with a stabilizing agent such as a carbohydrate. In hybridizations, the probe may be deployed in an aqueous solution containing salts (e.g., NaCl), detergents (e.g., sodium dodecyl sulfate; SDS), and other components (e.g., Denhardt's solution, dry milk, salmon sperm DNA, etc.).

"Consensus sequence" refers to a nucleic acid sequence which has been resequenced to  
15 resolve uncalled bases, extended using XL-PCR kit (Perkin-Elmer, Norwalk CT) in the 5' and/or the 3' direction, and resequenced, or which has been assembled from the overlapping sequences of more than one Incyte Clone using a computer program for fragment assembly, such as the GELVIEW Fragment Assembly system (GCG, Madison WI). Some sequences have been both extended and assembled to produce the consensus sequence.

20       The term "correlates with expression of a polynucleotide" indicates that the detection of the presence of nucleic acids, the same or related to a nucleic acid sequence encoding CJPDZ, by northern analysis is indicative of the presence of nucleic acids encoding CJPDZ in a sample, and thereby correlates with expression of the transcript from the polynucleotide encoding CJPDZ.

A "deletion" refers to a change in the amino acid or nucleotide sequence that results in the  
25 absence of one or more amino acid residues or nucleotides.

The term "derivative" refers to the chemical modification of a polypeptide sequence, or a polynucleotide sequence. Chemical modifications of a polynucleotide sequence can include, for example, replacement of hydrogen by an alkyl, acyl, or amino group. A derivative polynucleotide encodes a polypeptide which retains at least one biological or immunological function of the  
30 natural molecule. A derivative polypeptide is one modified by glycosylation, pegylation, or any similar process that retains at least one biological or immunological function of the polypeptide from which it was derived.

The term "similarity" refers to a degree of complementarity. There may be partial similarity or complete similarity. The word "identity" may substitute for the word "similarity." A

partially complementary sequence that at least partially inhibits an identical sequence from hybridizing to a target nucleic acid is referred to as "substantially similar." The inhibition of hybridization of the completely complementary sequence to the target sequence may be examined using a hybridization assay (Southern or northern blot, solution hybridization, and the like) under conditions of reduced stringency. A substantially similar sequence or hybridization probe will compete for and inhibit the binding of a completely similar (identical) sequence to the target sequence under conditions of reduced stringency. This is not to say that conditions of reduced stringency are such that non-specific binding is permitted, as reduced stringency conditions require that the binding of two sequences to one another be a specific (i.e., a selective) interaction.

10 The absence of non-specific binding may be tested by the use of a second target sequence which lacks even a partial degree of complementarity (e.g., less than about 30% similarity or identity). In the absence of non-specific binding, the substantially similar sequence or probe will not hybridize to the second non-complementary target sequence.

The phrases "percent identity" or "% identity" refer to the percentage of sequence similarity found in a comparison of two or more amino acid or nucleic acid sequences. Percent identity can be determined electronically, e.g., by using the MEGALIGN program (DNASTAR) which creates alignments between two or more sequences according to methods selected by the user, e.g., the clustal method. (See, e.g., Higgins, D.G. and P.M. Sharp (1988) Gene 73:237-244.) The clustal algorithm groups sequences into clusters by examining the distances between all pairs.

20 The clusters are aligned pairwise and then in groups. The percentage similarity between two amino acid sequences, e.g., sequence A and sequence B, is calculated by dividing the length of sequence A, minus the number of gap residues in sequence A, minus the number of gap residues in sequence B, into the sum of the residue matches between sequence A and sequence B, times one hundred. Gaps of low or of no similarity between the two amino acid sequences are not included in determining percentage similarity. Percent identity between nucleic acid sequences can also be counted or calculated by other methods known in the art, e.g., the Jotun Hein method. (See, e.g., Hein, J. (1990) Methods Enzymol. 183:626-645.) Identity between sequences can also be determined by other methods known in the art, e.g., by varying hybridization conditions.

25

"Human artificial chromosomes" (HACs) are linear microchromosomes which may contain DNA sequences of about 6 kb to 10 Mb in size, and which contain all of the elements required for stable mitotic chromosome segregation and maintenance.

30

The term "humanized antibody" refers to antibody molecules in which the amino acid sequence in the non-antigen binding regions has been altered so that the antibody more closely resembles a human antibody, and still retains its original binding ability.

"Hybridization" refers to any process by which a strand of nucleic acid binds with a complementary strand through base pairing.

The term "hybridization complex" refers to a complex formed between two nucleic acid sequences by virtue of the formation of hydrogen bonds between complementary bases. A  
5 hybridization complex may be formed in solution (e.g.,  $C_0t$  or  $R_0t$  analysis) or formed between one nucleic acid sequence present in solution and another nucleic acid sequence immobilized on a solid support (e.g., paper, membranes, filters, chips, pins or glass slides, or any other appropriate substrate to which cells or their nucleic acids have been fixed).

The words "insertion" or "addition" refer to changes in an amino acid or nucleotide  
10 sequence resulting in the addition of one or more amino acid residues or nucleotides, respectively, to the sequence found in the naturally occurring molecule.

"Immune response" can refer to conditions associated with inflammation, trauma, immune disorders, or infectious or genetic disease, etc. These conditions can be characterized by expression of various factors, e.g., cytokines, chemokines, and other signaling molecules, which  
15 may affect cellular and systemic defense systems.

The term "microarray" refers to an arrangement of distinct polynucleotides on a substrate.

The terms "element" or "array element" in a microarray context, refer to hybridizable polynucleotides arranged on the surface of a substrate.

The term "modulate" refers to a change in the activity of CJPDZ. For example,  
20 modulation may cause an increase or a decrease in protein activity, binding characteristics, or any other biological, functional, or immunological properties of CJPDZ.

The phrases "nucleic acid" or "nucleic acid sequence," as used herein, refer to a nucleotide, oligonucleotide, polynucleotide, or any fragment thereof. These phrases also refer to DNA or RNA of genomic or synthetic origin which may be single-stranded or double-stranded  
25 and may represent the sense or the antisense strand, to peptide nucleic acid (PNA), or to any DNA-like or RNA-like material. In this context, "fragments" refers to those nucleic acid sequences which comprise a region of unique polynucleotide sequence that specifically identifies SEQ ID NO:2, for example, as distinct from any other sequence in the same genome. For example, a fragment of SEQ ID NO:2 is useful in hybridization and amplification technologies  
30 and in analogous methods that distinguish SEQ ID NO:2 from related polynucleotide sequences. A fragment of SEQ ID NO:2 is at least about 15-20 nucleotides in length. The precise length of the fragment of SEQ ID NO:2 and the region of SEQ ID NO:2 to which the fragment corresponds are routinely determinable by one of ordinary skill in the art based on the intended purpose for the fragment. In some cases, a fragment, when translated, would produce polypeptides retaining some

functional characteristic, e.g., antigenicity, or structural domain characteristic, e.g., ATP-binding site, of the full-length polypeptide.

The terms "operably associated" or "operably linked" refer to functionally related nucleic acid sequences. A promoter is operably associated or operably linked with a coding sequence if  
5 the promoter controls the translation of the encoded polypeptide. While operably associated or operably linked nucleic acid sequences can be contiguous and in the same reading frame, certain genetic elements, e.g., repressor genes, are not contiguously linked to the sequence encoding the polypeptide but still bind to operator sequences that control expression of the polypeptide.

The term "oligonucleotide" refers to a nucleic acid sequence of at least about 6 nucleotides  
10 to 60 nucleotides, preferably about 15 to 30 nucleotides, and most preferably about 20 to 25 nucleotides, which can be used in PCR amplification or in a hybridization assay or microarray. "Oligonucleotide" is substantially equivalent to the terms "amplimer," "primer," "oligomer," and "probe," as these terms are commonly defined in the art.

"Peptide nucleic acid" (PNA) refers to an antisense molecule or anti-gene agent which  
15 comprises an oligonucleotide of at least about 5 nucleotides in length linked to a peptide backbone of amino acid residues ending in lysine. The terminal lysine confers solubility to the composition. PNAs preferentially bind complementary single stranded DNA or RNA and stop transcript elongation, and may be pegylated to extend their lifespan in the cell.

The term "sample" is used in its broadest sense. A sample suspected of containing nucleic  
20 acids encoding CJPDZ, or fragments thereof, or CJPDZ itself, may comprise a bodily fluid; an extract from a cell, chromosome, organelle, or membrane isolated from a cell; a cell; genomic DNA, RNA, or cDNA, in solution or bound to a substrate; a tissue; a tissue print; etc.

The terms "specific binding" or "specifically binding" refer to that interaction between a  
25 protein or peptide and an agonist, an antibody, or an antagonist. The interaction is dependent upon the presence of a particular structure of the protein, e.g., the antigenic determinant or epitope, recognized by the binding molecule. For example, if an antibody is specific for epitope "A," the presence of a polypeptide containing the epitope A, or the presence of free unlabeled A, in a reaction containing free labeled A and the antibody will reduce the amount of labeled A that binds to the antibody.

30 The term "stringent conditions" refers to conditions which permit hybridization between polynucleotides and the claimed polynucleotides. Stringent conditions can be defined by salt concentration, the concentration of organic solvent, e.g., formamide, temperature, and other conditions well known in the art. In particular, stringency can be increased by reducing the concentration of salt, increasing the concentration of formamide, or raising the hybridization

temperature.

The term "substantially purified" refers to nucleic acid or amino acid sequences that are removed from their natural environment and are isolated or separated, and are at least about 60% free, preferably about 75% free, and most preferably about 90% free from other components with which they are naturally associated.

A "substitution" refers to the replacement of one or more amino acids or nucleotides by different amino acids or nucleotides, respectively.

"Substrate" refers to any suitable rigid or semi-rigid support including membranes, filters, chips, slides, wafers, fibers, magnetic or nonmagnetic beads, gels, tubing, plates, polymers, microparticles and capillaries. The substrate can have a variety of surface forms, such as wells, trenches, pins, channels and pores, to which polynucleotides or polypeptides are bound.

"Transformation" describes a process by which exogenous DNA enters and changes a recipient cell. Transformation may occur under natural or artificial conditions according to various methods well known in the art, and may rely on any known method for the insertion of foreign nucleic acid sequences into a prokaryotic or eukaryotic host cell. The method for transformation is selected based on the type of host cell being transformed and may include, but is not limited to, viral infection, electroporation, heat shock, lipofection, and particle bombardment. The term "transformed" cells includes stably transformed cells in which the inserted DNA is capable of replication either as an autonomously replicating plasmid or as part of the host chromosome, as well as transiently transformed cells which express the inserted DNA or RNA for limited periods of time.

A "variant" of CJPZ polypeptides refers to an amino acid sequence that is altered by one or more amino acid residues. The variant may have "conservative" changes, wherein a substituted amino acid has similar structural or chemical properties (e.g., replacement of leucine with isoleucine). More rarely, a variant may have "nonconservative" changes (e.g., replacement of glycine with tryptophan). Analogous minor variations may also include amino acid deletions or insertions, or both. Guidance in determining which amino acid residues may be substituted, inserted, or deleted without abolishing biological or immunological activity may be found using computer programs well known in the art, for example, LASERGENE software (DNASTAR).

The term "variant," when used in the context of a polynucleotide sequence, may encompass a polynucleotide sequence related to CJPZ. This definition may also include, for example, "allelic" (as defined above), "splice," "species," or "polymorphic" variants. A splice variant may have significant identity to a reference molecule, but will generally have a greater or lesser number of polynucleotides due to alternate splicing of exons during mRNA processing. The

corresponding polypeptide may possess additional functional domains or an absence of domains. Species variants are polynucleotide sequences that vary from one species to another. The resulting polypeptides generally will have significant amino acid identity relative to each other. A polymorphic variant is a variation in the polynucleotide sequence of a particular gene between individuals of a given species. Polymorphic variants also may encompass "single nucleotide polymorphisms" (SNPs) in which the polynucleotide sequence varies by one base. The presence of SNPs may be indicative of, for example, a certain population, a disease state, or a propensity for a disease state.

## THE INVENTION

The invention is based on the discovery of a new human cell junction PDZ protein (CJPDZ), the polynucleotides encoding CJPDZ, and the use of these compositions for the diagnosis, treatment, or prevention of cancer, neurological disorders, and developmental disorders.

Nucleic acids encoding the CJPDZ of the present invention were identified in Incyte Clone 1974337H1 from the umbilical cord mononuclear cell cDNA library (UCMCL5T01) using a computer search for nucleotide and/or amino acid sequence alignments. A consensus sequence, SEQ ID NO:2, was derived from the following overlapping and/or extended nucleic acid sequences: Incyte Clones 1974337H1 (UCMCL5T01), 4921529H1 (TESTNOT11), 3606614H1 (LUNGNOT30), 1211072H1 (BRSTNOT02), and NCBI nucleotide identification numbers g2063575 and g2064159.

In one embodiment, the invention encompasses a polypeptide comprising the amino acid sequence of SEQ ID NO:1, as shown in Figures 1A, 1B, and 1C. CJPDZ is 233 amino acids in length and has five potential protein kinase C phosphorylation sites at S52, T89, S181, T189, and T205. CJPDZ has chemical and structural similarity with C. elegans LIN-7 (GI 1685067; SEQ ID NO:3). CJPDZ and LIN-7 share 53% identity overall and 69% identity within the region from L25 to R204 of CJPDZ and from L117 to R295 of LIN-7, as shown in Figure 2. Within this region, CJPDZ contains a putative PDZ domain from R107 to T189 which shares 82% sequence identity with the PDZ domain of LIN-7. The GD dipeptide and asparagine residue found in nearly all PDZ domains are conserved in CJPDZ at G152, D153, and N159. In addition, the putative PDZ domain of CJPDZ contains eleven glycine residues, consistent with the glycine-rich nature of nearly all PDZ domains. A fragment of SEQ ID NO:2 from about nucleotide 432 to about nucleotide 461 is useful in hybridization or amplification technologies to identify SEQ ID NO:2 and to distinguish between SEQ ID NO:2 and a related sequence. Northern analysis shows the expression of this sequence in mononuclear cells derived from umbilical cord blood, in the testis, in fetal lung, and in breast tissue.



The invention also encompasses CJPDZ variants. A preferred CJPDZ variant is one which has at least about 80%, more preferably at least about 90%, and most preferably at least about 95% amino acid sequence identity to the CJPDZ amino acid sequence, and which contains at least one functional or structural characteristic of CJPDZ.

5       The invention also encompasses polynucleotides which encode CJPDZ. In a particular embodiment, the invention encompasses a polynucleotide sequence comprising the sequence of SEQ ID NO:2, which encodes CJPDZ.

      The invention also encompasses a variant of a polynucleotide sequence encoding CJPDZ. In particular, such a variant polynucleotide sequence will have at least about 70%, more preferably at least about 85%, and most preferably at least about 95% polynucleotide sequence identity to the polynucleotide sequence encoding CJPDZ. A particular aspect of the invention encompasses a variant of SEQ ID NO:2 which has at least about 70%, more preferably at least about 85%, and most preferably at least about 95% polynucleotide sequence identity to SEQ ID NO:2. Any one of the polynucleotide variants described above can encode an amino acid sequence which contains at  
10       least one functional or structural characteristic of CJPDZ.  
15

      It will be appreciated by those skilled in the art that as a result of the degeneracy of the genetic code, a multitude of polynucleotide sequences encoding CJPDZ, some bearing minimal similarity to the polynucleotide sequences of any known and naturally occurring gene, may be produced. Thus, the invention contemplates each and every possible variation of polynucleotide  
20       sequence that could be made by selecting combinations based on possible codon choices. These combinations are made in accordance with the standard triplet genetic code as applied to the polynucleotide sequence of naturally occurring CJPDZ, and all such variations are to be considered as being specifically disclosed.

      Although nucleotide sequences which encode CJPDZ and its variants are preferably  
25       capable of hybridizing to the nucleotide sequence of the naturally occurring CJPDZ under appropriately selected conditions of stringency, it may be advantageous to produce nucleotide sequences encoding CJPDZ or its derivatives possessing a substantially different codon usage, e.g., inclusion of non-naturally occurring codons. Codons may be selected to increase the rate at which expression of the peptide occurs in a particular prokaryotic or eukaryotic host in accordance  
30       with the frequency with which particular codons are utilized by the host. Other reasons for substantially altering the nucleotide sequence encoding CJPDZ and its derivatives without altering the encoded amino acid sequences include the production of RNA transcripts having more desirable properties, such as a greater half-life, than transcripts produced from the naturally occurring sequence.

The invention also encompasses production of DNA sequences which encode CJPDZ and CJPDZ derivatives, or fragments thereof, entirely by synthetic chemistry. After production, the synthetic sequence may be inserted into any of the many available expression vectors and cell systems using reagents well known in the art. Moreover, synthetic chemistry may be used to  
5 introduce mutations into a sequence encoding CJPDZ or any fragment thereof.

Also encompassed by the invention are polynucleotide sequences that are capable of hybridizing to the claimed polynucleotide sequences, and, in particular, to those shown in SEQ ID NO:2, or to a fragment of SEQ ID NO:2, under various conditions of stringency. (See, e.g., Wahl, G.M. and S.L. Berger (1987) *Methods Enzymol.* 152:399-407; Kimmel, A.R. (1987) *Methods*  
10 *Enzymol.* 152:507-511.) For example, stringent salt concentration will ordinarily be less than about 750 mM NaCl and 75 mM trisodium citrate, preferably less than about 500 mM NaCl and 50 mM trisodium citrate, and most preferably less than about 250 mM NaCl and 25 mM trisodium citrate. Low stringency hybridization can be obtained in the absence of organic solvent, e.g., formamide, while high stringency hybridization can be obtained in the presence of at least about  
15 35% formamide, and most preferably at least about 50% formamide. Stringent temperature conditions will ordinarily include temperatures of at least about 30°C, more preferably of at least about 37°C, and most preferably of at least about 42°C. Varying additional parameters, such as hybridization time, the concentration of detergent, e.g., sodium dodecyl sulfate (SDS), and the inclusion or exclusion of carrier DNA, are well known to those skilled in the art. Various levels of  
20 stringency are accomplished by combining these various conditions as needed. In a preferred embodiment, hybridization will occur at 30°C in 750 mM NaCl, 75 mM trisodium citrate, and 1% SDS. In a more preferred embodiment, hybridization will occur at 37°C in 500 mM NaCl, 50 mM trisodium citrate, 1% SDS, 35% formamide, and 100 µg/ml denatured salmon sperm DNA (ssDNA). In a most preferred embodiment, hybridization will occur at 42°C in 250 mM NaCl, 25  
25 mM trisodium citrate, 1% SDS, 50 % formamide, and 200 µg/ml ssDNA. Useful variations on these conditions will be readily apparent to those skilled in the art.

The washing steps which follow hybridization can also vary in stringency. Wash stringency conditions can be defined by salt concentration and by temperature. As above, wash stringency can be increased by decreasing salt concentration or by increasing temperature. For  
30 example, stringent salt concentration for the wash steps will preferably be less than about 30 mM NaCl and 3 mM trisodium citrate, and most preferably less than about 15 mM NaCl and 1.5 mM trisodium citrate. Stringent temperature conditions for the wash steps will ordinarily include temperature of at least about 25°C, more preferably of at least about 42°C, and most preferably of at least about 68°C. In a preferred embodiment, wash steps will occur at 25°C in 30 mM NaCl, 3

mM trisodium citrate, and 0.1% SDS. In a more preferred embodiment, wash steps will occur at 42°C in 15 mM NaCl, 1.5 mM trisodium citrate, and 0.1% SDS. In a most preferred embodiment, wash steps will occur at 68°C in 15 mM NaCl, 1.5 mM trisodium citrate, and 0.1% SDS.

Additional variations on these conditions will be readily apparent to those skilled in the art.

- 5           Methods for DNA sequencing are well known in the art and may be used to practice any of the embodiments of the invention. The methods may employ such enzymes as the Klenow fragment of DNA polymerase I, SEQUENASE (US Biochemical, Cleveland OH), Taq polymerase (Perkin-Elmer), thermostable T7 polymerase (Amersham Pharmacia Biotech, Piscataway NJ), or combinations of polymerases and proofreading exonucleases such as those found in the
- 10   ELONGASE amplification system (Life Technologies, Gaithersburg MD). Preferably, sequence preparation is automated with machines such as the Robbins Hydra microdispenser (Robbins Scientific, Sunnyvale CA), Hamilton MICROLAB 2200 (Hamilton, Reno NV), Peltier Thermal Cycler 200 (PTC200; MJ Research, Watertown MA) and the ABI CATALYST 800 (Perkin-Elmer). Sequencing is then carried out using either ABI 373 or 377 DNA sequencing systems
- 15   (Perkin-Elmer) or the MEGABACE 1000 DNA sequencing system (Molecular Dynamics, Sunnyvale CA). The resulting sequences are analyzed using a variety of algorithms which are well known in the art. (See, e.g., Ausubel, F.M. (1997) Short Protocols in Molecular Biology, John Wiley & Sons, New York NY, unit 7.7; Meyers, R.A. (1995) Molecular Biology and Biotechnology, Wiley VCH, New York NY, pp. 856-853.)
- 20           The nucleic acid sequences encoding CJPDZ may be extended utilizing a partial nucleotide sequence and employing various PCR-based methods known in the art to detect upstream sequences, such as promoters and regulatory elements. For example, one method which may be employed, restriction-site PCR, uses universal and nested primers to amplify unknown sequence from genomic DNA within a cloning vector. (See, e.g., Sarkar, G. (1993) PCR Methods
- 25   Applic. 2:318-322.) Another method, inverse PCR, uses primers that extend in divergent directions to amplify unknown sequence from a circularized template. The template is derived from restriction fragments comprising a known genomic locus and surrounding sequences. (See, e.g., Triglia, T. et al. (1988) Nucleic Acids Res. 16:8186.) A third method, capture PCR, involves PCR amplification of DNA fragments adjacent to known sequences in human and yeast artificial
- 30   chromosome DNA. (See, e.g., Lagerstrom, M. et al. (1991) PCR Methods Applic. 1:111-119.) In this method, multiple restriction enzyme digestions and ligations may be used to insert an engineered double-stranded sequence into a region of unknown sequence before performing PCR. Other methods which may be used to retrieve unknown sequences are known in the art. (See, e.g., Parker, J.D. et al. (1991) Nucleic Acids Res. 19:3055-3060). Additionally, one may use PCR,

5 nested primers, and PROMOTERFINDER libraries (Clontech, Palo Alto CA) to walk genomic DNA. This procedure avoids the need to screen libraries and is useful in finding intron/exon junctions. For all PCR-based methods, primers may be designed using commercially available software, such as OLIGO 4.06 Primer Analysis software (National Biosciences, Plymouth MN) or  
5 another appropriate program, to be about 22 to 30 nucleotides in length, to have a GC content of about 50% or more, and to anneal to the template at temperatures of about 68°C to 72°C.

When screening for full-length cDNAs, it is preferable to use libraries that have been size-selected to include larger cDNAs. In addition, random-primed libraries, which often include sequences containing the 5' regions of genes, are preferable for situations in which an oligo d(T)  
10 library does not yield a full-length cDNA. Genomic libraries may be useful for extension of sequence into 5' non-transcribed regulatory regions.

Capillary electrophoresis systems which are commercially available may be used to analyze the size or confirm the nucleotide sequence of sequencing or PCR products. In particular, capillary sequencing may employ flowable polymers for electrophoretic separation, four different  
15 nucleotide-specific, laser-stimulated fluorescent dyes, and a charge coupled device camera for detection of the emitted wavelengths. Output/light intensity may be converted to electrical signal using appropriate software (e.g., GENOTYPER and SEQUENCE NAVIGATOR, Perkin-Elmer), and the entire process from loading of samples to computer analysis and electronic data display may be computer controlled. Capillary electrophoresis is especially preferable for sequencing  
20 small DNA fragments which may be present in limited amounts in a particular sample.

In another embodiment of the invention, polynucleotide sequences or fragments thereof which encode CJPDZ may be cloned in recombinant DNA molecules that direct expression of CJPDZ, or fragments or functional equivalents thereof, in appropriate host cells. Due to the inherent degeneracy of the genetic code, other DNA sequences which encode substantially the  
25 same or a functionally equivalent amino acid sequence may be produced and used to express CJPDZ.

The nucleotide sequences of the present invention can be engineered using methods generally known in the art in order to alter CJPDZ-encoding sequences for a variety of purposes including, but not limited to, modification of the cloning, processing, and/or expression of the  
30 gene product. DNA shuffling by random fragmentation and PCR reassembly of gene fragments and synthetic oligonucleotides may be used to engineer the nucleotide sequences. For example, oligonucleotide-mediated site-directed mutagenesis may be used to introduce mutations that create new restriction sites, alter glycosylation patterns, change codon preference, produce splice variants, and so forth.

In another embodiment, sequences encoding CJPDPZ may be synthesized, in whole or in part, using chemical methods well known in the art. (See, e.g., Caruthers, M.H. et al. (1980) Nucleic Acids Symp. Ser. 7:215-223, and Horn, T. et al. (1980) Nucleic Acids Symp. Ser. 7:225-232.) Alternatively, CJPDPZ itself or a fragment thereof may be synthesized using chemical methods. For example, peptide synthesis can be performed using various solid-phase techniques. (See, e.g., Roberge, J.Y. et al. (1995) Science 269:202-204.) Automated synthesis may be achieved using the ABI 431A Peptide Synthesizer (Perkin-Elmer). Additionally, the amino acid sequence of CJPDPZ, or any part thereof, may be altered during direct synthesis and/or combined with sequences from other proteins, or any part thereof, to produce a variant polypeptide.

The peptide may be substantially purified by preparative high performance liquid chromatography. (See, e.g., Chiez, R.M. and F.Z. Regnier (1990) Methods Enzymol. 182:392-421.) The composition of the synthetic peptides may be confirmed by amino acid analysis or by sequencing. (See, e.g., Creighton, T. (1984) Proteins, Structures and Molecular Properties, WH Freeman, New York NY.)

In order to express a biologically active CJPDPZ, the nucleotide sequences encoding CJPDPZ or derivatives thereof may be inserted into an appropriate expression vector, i.e., a vector which contains the necessary elements for transcriptional and translational control of the inserted coding sequence in a suitable host. These elements include regulatory sequences, such as enhancers, constitutive and inducible promoters, and 5' and 3' untranslated regions in the vector and in polynucleotide sequences encoding CJPDPZ. Such elements may vary in their strength and specificity. Specific initiation signals may also be used to achieve more efficient translation of sequences encoding CJPDPZ. Such signals include the ATG initiation codon and adjacent sequences, e.g. the Kozak sequence. In cases where sequences encoding CJPDPZ and its initiation codon and upstream regulatory sequences are inserted into the appropriate expression vector, no additional transcriptional or translational control signals may be needed. However, in cases where only coding sequence, or a fragment thereof, is inserted, exogenous translational control signals including an in-frame ATG initiation codon should be provided by the vector. Exogenous translational elements and initiation codons may be of various origins, both natural and synthetic. The efficiency of expression may be enhanced by the inclusion of enhancers appropriate for the particular host cell system used. (See, e.g., Scharf, D. et al. (1994) Results Probl. Cell Differ. 20:125-162.)

Methods which are well known to those skilled in the art may be used to construct expression vectors containing sequences encoding CJPDPZ and appropriate transcriptional and translational control elements. These methods include in vitro recombinant DNA techniques,

synthetic techniques, and in vivo genetic recombination. (See, e.g., Sambrook, J. et al. (1989) Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Press, Plainview NY, ch. 4, 8, and 16-17; Ausubel, F.M. et al. (1995) Current Protocols in Molecular Biology, John Wiley & Sons, New York NY, ch. 9, 13, and 16.)

5           A variety of expression vector/host systems may be utilized to contain and express sequences encoding CJPDZ. These include, but are not limited to, microorganisms such as bacteria transformed with recombinant bacteriophage, plasmid, or cosmid DNA expression vectors; yeast transformed with yeast expression vectors; insect cell systems infected with viral expression vectors (e.g., baculovirus); plant cell systems transformed with viral expression vectors  
10 (e.g., cauliflower mosaic virus, CaMV, or tobacco mosaic virus, TMV) or with bacterial expression vectors (e.g., Ti or pBR322 plasmids); or animal cell systems. The invention is not limited by the host cell employed.

          In bacterial systems, a number of cloning and expression vectors may be selected depending upon the use intended for polynucleotide sequences encoding CJPDZ. For example,  
15 routine cloning, subcloning, and propagation of polynucleotide sequences encoding CJPDZ can be achieved using a multifunctional E. coli vector such as PBLUESCRIPT (Stratagene, La Jolla CA) or PSPORT1 plasmid (Life Technologies). Ligation of sequences encoding CJPDZ into the vector's multiple cloning site disrupts the *lacZ* gene, allowing a colorimetric screening procedure for identification of transformed bacteria containing recombinant molecules. In addition, these  
20 vectors may be useful for in vitro transcription, dideoxy sequencing, single strand rescue with helper phage, and creation of nested deletions in the cloned sequence. (See, e.g., Van Heeke, G. and S.M. Schuster (1989) J. Biol. Chem. 264:5503-5509.) When large quantities of CJPDZ are needed, e.g. for the production of antibodies, vectors which direct high level expression of CJPDZ may be used. For example, vectors containing the strong, inducible T5 or T7 bacteriophage  
25 promoter may be used.

          Yeast expression systems may be used for production of CJPDZ. A number of vectors containing constitutive or inducible promoters, such as alpha factor, alcohol oxidase, and PGH promoters, may be used in the yeast Saccharomyces cerevisiae or Pichia pastoris. In addition, such vectors direct either the secretion or intracellular retention of expressed proteins and enable  
30 integration of foreign sequences into the host genome for stable propagation. (See, e.g., Ausubel, 1995, supra; Bitter, G.A. et al. (1987) Methods Enzymol. 153:516-544; and Scorer, C.A. et al. (1994) Bio/Technology 12:181-184.)

          Plant systems may also be used for expression of CJPDZ. Transcription of sequences encoding CJPDZ may be driven by viral promoters, e.g., the 35S and 19S promoters of CaMV

used alone or in combination with the omega leader sequence from TMV (Takamatsu, N. (1987) EMBO J. 6:307-311). Alternatively, plant promoters such as the small subunit of RUBISCO or heat shock promoters may be used. (See, e.g., Coruzzi, G. et al. (1984) EMBO J. 3:1671-1680; Broglie, R. et al. (1984) Science 224:838-843; and Winter, J. et al. (1991) Results Probl. Cell Differ. 17:85-105.) These constructs can be introduced into plant cells by direct DNA transformation or pathogen-mediated transfection. (See, e.g., The McGraw Hill Yearbook of Science and Technology (1992) McGraw Hill, New York NY, pp. 191-196.)

In mammalian cells, a number of viral-based expression systems may be utilized. In cases where an adenovirus is used as an expression vector, sequences encoding CJPDPZ may be ligated into an adenovirus transcription/translation complex consisting of the late promoter and tripartite leader sequence. Insertion in a non-essential E1 or E3 region of the viral genome may be used to obtain infective virus which expresses CJPDPZ in host cells. (See, e.g., Logan, J. and T. Shenk (1984) Proc. Natl. Acad. Sci. USA 81:3655-3659.) In addition, transcription enhancers, such as the Rous sarcoma virus (RSV) enhancer, may be used to increase expression in mammalian host cells. SV40 or EBV-based vectors may also be used for high-level protein expression.

Human artificial chromosomes (HACs) may also be employed to deliver larger fragments of DNA than can be contained in and expressed from a plasmid. HACs of about 6 kb to 10 Mb are constructed and delivered via conventional delivery methods (liposomes, polycationic amino polymers, or vesicles) for therapeutic purposes. (See, e.g., Harrington, J.J. et al. (1997) Nat. Genet. 15:345-355.)

For long term production of recombinant proteins in mammalian systems, stable expression of CJPDPZ in cell lines is preferred. For example, sequences encoding CJPDPZ can be transformed into cell lines using expression vectors which may contain viral origins of replication and/or endogenous expression elements and a selectable marker gene on the same or on a separate vector. Following the introduction of the vector, cells may be allowed to grow for about 1 to 2 days in enriched media before being switched to selective media. The purpose of the selectable marker is to confer resistance to a selective agent, and its presence allows growth and recovery of cells which successfully express the introduced sequences. Resistant clones of stably transformed cells may be propagated using tissue culture techniques appropriate to the cell type.

Any number of selection systems may be used to recover transformed cell lines. These include, but are not limited to, the herpes simplex virus thymidine kinase and adenine phosphoribosyltransferase genes, for use in *tk* or *aprt* cells, respectively. (See, e.g., Wigler, M. et al. (1977) Cell 11:223-232; Lowy, I. et al. (1980) Cell 22:817-823.) Also, antimetabolite, antibiotic, or herbicide resistance can be used as the basis for selection. For example, *dhfr* confers

resistance to methotrexate; *neo* confers resistance to the aminoglycosides, neomycin and G-418; and *als* or *pat* confer resistance to chlorsulfuron and phosphinotricin acetyltransferase, respectively. (See, e.g., Wigler, M. et al. (1980) Proc. Natl. Acad. Sci. USA 77:3567-3570; Colbere-Garapin, F. et al. (1981) J. Mol. Biol. 150:1-14.) Additional selectable genes have been described, e.g., *trpB* and *hisD*, which alter cellular requirements for metabolites. (See, e.g., Hartman, S.C. and R.C. Mulligan (1988) Proc. Natl. Acad. Sci. USA 85:8047-8051.) Visible markers, e.g., anthocyanins, green fluorescent proteins (GFP; Clontech),  $\beta$  glucuronidase and its substrate  $\beta$ -glucuronide, or luciferase and its substrate luciferin may be used. These markers can be used not only to identify transformants, but also to quantify the amount of transient or stable protein expression attributable to a specific vector system. (See, e.g., Rhodes, C.A. (1995) Methods Mol. Biol. 55:121-131.)

Although the presence/absence of marker gene expression suggests that the gene of interest is also present, the presence and expression of the gene may need to be confirmed. For example, if the sequence encoding CJPDZ is inserted within a marker gene sequence, transformed cells containing sequences encoding CJPDZ can be identified by the absence of marker gene function. Alternatively, a marker gene can be placed in tandem with a sequence encoding CJPDZ under the control of a single promoter. Expression of the marker gene in response to induction or selection usually indicates expression of the tandem gene as well.

In general, host cells that contain the nucleic acid sequence encoding CJPDZ and that express CJPDZ may be identified by a variety of procedures known to those of skill in the art. These procedures include, but are not limited to, DNA-DNA or DNA-RNA hybridizations, PCR amplification, and protein bioassay or immunoassay techniques which include membrane, solution, or chip based technologies for the detection and/or quantification of nucleic acid or protein sequences.

Immunological methods for detecting and measuring the expression of CJPDZ using either specific polyclonal or monoclonal antibodies are known in the art. Examples of such techniques include enzyme-linked immunosorbent assays (ELISAs), radioimmunoassays (RIAs), and fluorescence activated cell sorting (FACS). A two-site, monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two non-interfering epitopes on CJPDZ is preferred, but a competitive binding assay may be employed. These and other assays are well known in the art. (See, e.g., Hampton, R. et al. (1990) Serological Methods, a Laboratory Manual, APS Press, St. Paul MN, Sect. IV; Coligan, J.E. et al. (1997) Current Protocols in Immunology, Greene Pub. Associates and Wiley-Interscience, New York NY; and Pound, J.D. (1998) Immunochemical Protocols, Humana Press, Totowa NJ).



A wide variety of labels and conjugation techniques are known by those skilled in the art and may be used in various nucleic acid and amino acid assays. Means for producing labeled hybridization or PCR probes for detecting sequences related to polynucleotides encoding CJPDZ include oligolabeling, nick translation, end-labeling, or PCR amplification using a labeled nucleotide. Alternatively, the sequences encoding CJPDZ, or any fragments thereof, may be cloned into a vector for the production of an mRNA probe. Such vectors are known in the art, are commercially available, and may be used to synthesize RNA probes in vitro by addition of an appropriate RNA polymerase such as T7, T3, or SP6 and labeled nucleotides. These procedures may be conducted using a variety of commercially available kits, such as those provided by Amersham Pharmacia Biotech, Promega (Madison WI), and US Biochemical. Suitable reporter molecules or labels which may be used for ease of detection include radionuclides, enzymes, fluorescent, chemiluminescent, or chromogenic agents, as well as substrates, cofactors, inhibitors, magnetic particles, and the like.

Host cells transformed with nucleotide sequences encoding CJPDZ may be cultured under conditions suitable for the expression and recovery of the protein from cell culture. The protein produced by a transformed cell may be secreted or retained intracellularly depending on the sequence and/or the vector used. As will be understood by those of skill in the art, expression vectors containing polynucleotides which encode CJPDZ may be designed to contain signal sequences which direct secretion of CJPDZ through a prokaryotic or eukaryotic cell membrane.

In addition, a host cell strain may be chosen for its ability to modulate expression of the inserted sequences or to process the expressed protein in the desired fashion. Such modifications of the polypeptide include, but are not limited to, acetylation, carboxylation, glycosylation, phosphorylation, lipidation, and acylation. Post-translational processing which cleaves a "prepro" form of the protein may also be used to specify protein targeting, folding, and/or activity.

Different host cells which have specific cellular machinery and characteristic mechanisms for post-translational activities (e.g., CHO, HeLa, MDCK, HEK293, and WI38), are available from the American Type Culture Collection (ATCC, Manassas VA) and may be chosen to ensure the correct modification and processing of the foreign protein.

In another embodiment of the invention, natural, modified, or recombinant nucleic acid sequences encoding CJPDZ may be ligated to a heterologous sequence resulting in translation of a fusion protein in any of the aforementioned host systems. For example, a chimeric CJPDZ protein containing a heterologous moiety that can be recognized by a commercially available antibody may facilitate the screening of peptide libraries for inhibitors of CJPDZ activity. Heterologous protein and peptide moieties may also facilitate purification of fusion proteins using

commercially available affinity matrices. Such moieties include, but are not limited to, glutathione S-transferase (GST), maltose binding protein (MBP), thioredoxin (Trx), calmodulin binding peptide (CBP), 6-His, FLAG, *c-myc*, and hemagglutinin (HA). GST, MBP, Trx, CBP, and 6-His enable purification of their cognate fusion proteins on immobilized glutathione, maltose, 5 phenylarsine oxide, calmodulin, and metal-chelate resins, respectively. FLAG, *c-myc*, and hemagglutinin (HA) enable immunoaffinity purification of fusion proteins using commercially available monoclonal and polyclonal antibodies that specifically recognize these epitope tags. A fusion protein may also be engineered to contain a proteolytic cleavage site located between the CJPDPZ encoding sequence and the heterologous protein sequence, so that CJPDPZ may be cleaved 10 away from the heterologous moiety following purification. Methods for fusion protein expression and purification are discussed in Ausubel (1995, *supra*, ch 10). A variety of commercially available kits may also be used to facilitate expression and purification of fusion proteins.

In a further embodiment of the invention, synthesis of radiolabeled CJPDPZ may be achieved *in vitro* using the TNT rabbit reticulocyte lysate or wheat germ extract systems 15 (Promega). These systems couple transcription and translation of protein-coding sequences operably associated with the T7, T3, or SP6 promoters. Translation takes place in the presence of a radiolabeled amino acid precursor, preferably <sup>35</sup>S-methionine.

Fragments of CJPDPZ may be produced not only by recombinant production, but also by direct peptide synthesis using solid-phase techniques. (See, e.g., Creighton, *supra* pp. 55-60.) 20 Protein synthesis may be performed by manual techniques or by automation. Automated synthesis may be achieved, for example, using the ABI 431A Peptide Synthesizer (Perkin-Elmer). Various fragments of CJPDPZ may be synthesized separately and then combined to produce the full length molecule.

## THERAPEUTICS

25 Chemical and structural similarity, e.g., in the context of sequences and motifs, exists between regions of CJPDPZ and the LIN-7 PDZ domain-containing protein. Therefore, CJPDPZ appears to be associated with disorders related to PDZ function, such as cancer, neurological disorders, and developmental disorders. In the treatment of such disorders associated with increased CJPDPZ expression or activity, it is desirable to decrease the expression or activity of 30 CJPDPZ. In the treatment of such disorders associated with decreased CJPDPZ expression or activity, it is desirable to increase the expression or activity of CJPDPZ.

Therefore, in one embodiment, CJPDPZ or a fragment or derivative thereof may be administered to a subject to treat or prevent a disorder associated with decreased expression or activity of CJPDPZ. Examples of such disorders include cancers such as adenocarcinoma,

leukemia, lymphoma, melanoma, myeloma, sarcoma, teratocarcinoma, and, in particular, cancers of the adrenal gland, bladder, bone, bone marrow, brain, breast, cervix, gall bladder, ganglia, gastrointestinal tract, heart, kidney, liver, lung, muscle, ovary, pancreas, parathyroid, penis, prostate, salivary glands, skin, spleen, testis, thymus, thyroid, and uterus; neurological disorders such as epilepsy, ischemic cerebrovascular disease, stroke, cerebral neoplasms, Alzheimer's disease, Pick's disease, Huntington's disease, dementia, Parkinson's disease and other extrapyramidal disorders, amyotrophic lateral sclerosis and other motor neuron disorders, progressive neural muscular atrophy, retinitis pigmentosa, hereditary ataxias, multiple sclerosis and other demyelinating diseases, bacterial and viral meningitis, brain abscess, subdural empyema, epidural abscess, suppurative intracranial thrombophlebitis, myelitis and radiculitis, viral central nervous system disease, prion diseases including kuru, Creutzfeldt-Jakob disease, and Gerstmann-Straussler-Scheinker syndrome, fatal familial insomnia, nutritional and metabolic diseases of the nervous system, neurofibromatosis, tuberous sclerosis, cerebelloretinal hemangioblastomatosis, encephalotrigeminal syndrome, mental retardation and other developmental disorders of the central nervous system, cerebral palsy, neuroskeletal disorders, autonomic nervous system disorders, cranial nerve disorders, spinal cord diseases, muscular dystrophy and other neuromuscular disorders, peripheral nervous system disorders, dermatomyositis and polymyositis, inherited, metabolic, endocrine, and toxic myopathies, myasthenia gravis, periodic paralysis, mental disorders including mood, anxiety, and schizophrenic disorders, akathisia, amnesia, catatonia, diabetic neuropathy, tardive dyskinesia, dystonias, paranoid psychoses, postherpetic neuralgia, and Tourette's disorder; and developmental disorders such as renal tubular acidosis, anemia, Cushing's syndrome, achondroplastic dwarfism, Duchenne and Becker muscular dystrophy, epilepsy, gonadal dysgenesis, WAGR syndrome (Wilms' tumor, aniridia, genitourinary abnormalities, and mental retardation), Smith-Magenis syndrome, myelodysplastic syndrome, hereditary mucoepithelial dysplasia, hereditary keratodermas, hereditary neuropathies such as Charcot-Marie-Tooth disease and neurofibromatosis, hypothyroidism, hydrocephalus, seizure disorders such as Sydenham's chorea and cerebral palsy, spina bifida, Williams syndrome, anencephaly, craniorachischisis, congenital glaucoma, cataract, sensorineural hearing loss, and any disorder associated with cell growth and differentiation, embryogenesis, and morphogenesis involving any tissue, organ, or system of a subject, e.g., the brain, adrenal gland, kidney, skeletal or reproductive system.

In another embodiment, a vector capable of expressing CJPZ or a fragment or derivative thereof may be administered to a subject to treat or prevent a disorder associated with decreased expression or activity of CJPZ including, but not limited to, those described above.

In a further embodiment, a pharmaceutical composition comprising a substantially purified CJPDZ in conjunction with a suitable pharmaceutical carrier may be administered to a subject to treat or prevent a disorder associated with decreased expression or activity of CJPDZ including, but not limited to, those provided above.

5 In still another embodiment, an agonist which modulates the activity of CJPDZ may be administered to a subject to treat or prevent a disorder associated with decreased expression or activity of CJPDZ including, but not limited to, those listed above.

In a further embodiment, an antagonist of CJPDZ may be administered to a subject to treat or prevent a disorder associated with increased expression or activity of CJPDZ. Such disorders  
10 may include, but are not limited to, the cancers, neurological disorders, and developmental disorders discussed above. In one aspect, an antibody which specifically binds CJPDZ may be used directly as an antagonist or indirectly as a targeting or delivery mechanism for bringing a pharmaceutical agent to cells or tissue which express CJPDZ.

In an additional embodiment, a vector expressing the complement of the polynucleotide  
15 encoding CJPDZ may be administered to a subject to treat or prevent a disorder associated with increased expression or activity of CJPDZ including, but not limited to, those described above.

In other embodiments, any of the proteins, antagonists, antibodies, agonists, complementary sequences, or vectors of the invention may be administered in combination with other appropriate therapeutic agents. Selection of the appropriate agents for use in combination  
20 therapy may be made by one of ordinary skill in the art, according to conventional pharmaceutical principles. The combination of therapeutic agents may act synergistically to effect the treatment or prevention of the various disorders described above. Using this approach, one may be able to achieve therapeutic efficacy with lower dosages of each agent, thus reducing the potential for adverse side effects.

25 An antagonist of CJPDZ may be produced using methods which are generally known in the art. In particular, purified CJPDZ may be used to produce antibodies or to screen libraries of pharmaceutical agents to identify those which specifically bind CJPDZ. Antibodies to CJPDZ may also be generated using methods that are well known in the art. Such antibodies may include, but are not limited to, polyclonal, monoclonal, chimeric, and single chain antibodies, Fab  
30 fragments, and fragments produced by a Fab expression library. Neutralizing antibodies (i.e., those which inhibit dimer formation) are especially preferred for therapeutic use.

For the production of antibodies, various hosts including goats, rabbits, rats, mice, humans, and others may be immunized by injection with CJPDZ or with any fragment or oligopeptide thereof which has immunogenic properties. Depending on the host species, various

adjuvants may be used to increase immunological response. Such adjuvants include, but are not limited to, Freund's, mineral gels such as aluminum hydroxide, and surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, KLH, and dinitrophenol. Among adjuvants used in humans, BCG (bacilli Calmette-Guerin) and Corynebacterium parvum are especially preferable.

It is preferred that the oligopeptides, peptides, or fragments used to induce antibodies to CJPDPZ have an amino acid sequence consisting of at least about 5 amino acids, and, more preferably, of at least about 10 amino acids. It is also preferable that these oligopeptides, peptides, or fragments are identical to a portion of the amino acid sequence of the natural protein and contain the entire amino acid sequence of a small, naturally occurring molecule. Short stretches of CJPDPZ amino acids may be fused with those of another protein, such as KLH, and antibodies to the chimeric molecule may be produced.

Monoclonal antibodies to CJPDPZ may be prepared using any technique which provides for the production of antibody molecules by continuous cell lines in culture. These include, but are not limited to, the hybridoma technique, the human B-cell hybridoma technique, and the EBV-hybridoma technique. (See, e.g., Kohler, G. et al. (1975) Nature 256:495-497; Kozbor, D. et al. (1985) J. Immunol. Methods 81:31-42; Cote, R.J. et al. (1983) Proc. Natl. Acad. Sci. USA 80:2026-2030; and Cole, S.P. et al. (1984) Mol. Cell Biol. 62:109-120.)

In addition, techniques developed for the production of "chimeric antibodies," such as the splicing of mouse antibody genes to human antibody genes to obtain a molecule with appropriate antigen specificity and biological activity, can be used. (See, e.g., Morrison, S.L. et al. (1984) Proc. Natl. Acad. Sci. USA 81:6851-6855; Neuberger, M.S. et al. (1984) Nature 312:604-608; and Takeda, S. et al. (1985) Nature 314:452-454.) Alternatively, techniques described for the production of single chain antibodies may be adapted, using methods known in the art, to produce CJPDPZ-specific single chain antibodies. Antibodies with related specificity, but of distinct idiotypic composition, may be generated by chain shuffling from random combinatorial immunoglobulin libraries. (See, e.g., Burton D.R. (1991) Proc. Natl. Acad. Sci. USA 88:10134-10137.)

Antibodies may also be produced by inducing in vivo production in the lymphocyte population or by screening immunoglobulin libraries or panels of highly specific binding reagents as disclosed in the literature. (See, e.g., Orlandi, R. et al. (1989) Proc. Natl. Acad. Sci. USA 86:3833-3837; Winter, G. et al. (1991) Nature 349:293-299.)

Antibody fragments which contain specific binding sites for CJPDPZ may also be generated. For example, such fragments include, but are not limited to, F(ab')<sub>2</sub> fragments

produced by pepsin digestion of the antibody molecule and Fab fragments generated by reducing the disulfide bridges of the F(ab')<sub>2</sub> fragments. Alternatively, Fab expression libraries may be constructed to allow rapid and easy identification of monoclonal Fab fragments with the desired specificity. (See, e.g., Huse, W.D. et al. (1989) Science 246:1275-1281.)

5 Various immunoassays may be used for screening to identify antibodies having the desired specificity. Numerous protocols for competitive binding or immunoradiometric assays using either polyclonal or monoclonal antibodies with established specificities are well known in the art. Such immunoassays typically involve the measurement of complex formation between CJPZ and its specific antibody. A two-site, monoclonal-based immunoassay utilizing  
10 monoclonal antibodies reactive to two non-interfering CJPZ epitopes is preferred, but a competitive binding assay may also be employed (Pound, *supra*).

Various methods such as Scatchard analysis in conjunction with radioimmunoassay techniques may be used to assess the affinity of antibodies for CJPZ. Affinity is expressed as an association constant,  $K_a$ , which is defined as the molar concentration of CJPZ-antibody complex  
15 divided by the molar concentrations of free antigen and free antibody under equilibrium conditions. The  $K_a$  determined for a preparation of polyclonal antibodies, which are heterogeneous in their affinities for multiple CJPZ epitopes, represents the average affinity, or avidity, of the antibodies for CJPZ. The  $K_a$  determined for a preparation of monoclonal antibodies, which are monospecific for a particular CJPZ epitope, represents a true measure of  
20 affinity. High-affinity antibody preparations with  $K_a$  ranging from about  $10^9$  to  $10^{12}$  l/mole are preferred for use in immunoassays in which the CJPZ-antibody complex must withstand rigorous manipulations. Low-affinity antibody preparations with  $K_a$  ranging from about  $10^6$  to  $10^7$  l/mole are preferred for use in immunopurification and similar procedures which ultimately require dissociation of CJPZ, preferably in active form, from the antibody (Catty, D. (1988)  
25 Antibodies, Volume I: A Practical Approach, IRL Press, Washington DC; Liddell, J.E. and A. Cryer (1991) A Practical Guide to Monoclonal Antibodies, John Wiley & Sons, New York NY).

The titer and avidity of polyclonal antibody preparations may be further evaluated to determine the quality and suitability of such preparations for certain downstream applications. For example, a polyclonal antibody preparation containing at least 1-2 mg specific antibody/ml,  
30 preferably 5-10 mg specific antibody/ml, is preferred for use in procedures requiring precipitation of CJPZ-antibody complexes. Procedures for evaluating antibody specificity, titer, and avidity, and guidelines for antibody quality and usage in various applications, are generally available. (See, e.g., Catty, *supra*, and Coligan et al. *supra*.)

In another embodiment of the invention, the polynucleotides encoding CJPZ, or any

fragment or complement thereof, may be used for therapeutic purposes. In one aspect, the complement of the polynucleotide encoding CJPDZ may be used in situations in which it would be desirable to block the transcription of the mRNA. In particular, cells may be transformed with sequences complementary to polynucleotides encoding CJPDZ. Thus, complementary molecules or fragments may be used to modulate CJPDZ activity, or to achieve regulation of gene function. Such technology is now well known in the art, and sense or antisense oligonucleotides or larger fragments can be designed from various locations along the coding or control regions of sequences encoding CJPDZ.

Expression vectors derived from retroviruses, adenoviruses, or herpes or vaccinia viruses, or from various bacterial plasmids, may be used for delivery of nucleotide sequences to the targeted organ, tissue, or cell population. Methods which are well known to those skilled in the art can be used to construct vectors to express nucleic acid sequences complementary to the polynucleotides encoding CJPDZ. (See, e.g., Sambrook, supra; Ausubel, 1995, supra.)

Genes encoding CJPDZ can be turned off by transforming a cell or tissue with expression vectors which express high levels of a polynucleotide, or fragment thereof, encoding CJPDZ. Such constructs may be used to introduce untranslatable sense or antisense sequences into a cell. Even in the absence of integration into the DNA, such vectors may continue to transcribe RNA molecules until they are disabled by endogenous nucleases. Transient expression may last for a month or more with a non-replicating vector, and may last even longer if appropriate replication elements are part of the vector system.

As mentioned above, modifications of gene expression can be obtained by designing complementary sequences or antisense molecules (DNA, RNA, or PNA) to the control, 5', or regulatory regions of the gene encoding CJPDZ. Oligonucleotides derived from the transcription initiation site, e.g., between about positions -10 and +10 from the start site, are preferred. Similarly, inhibition can be achieved using triple helix base-pairing methodology. Triple helix pairing is useful because it causes inhibition of the ability of the double helix to open sufficiently for the binding of polymerases, transcription factors, or regulatory molecules. Recent therapeutic advances using triplex DNA have been described in the literature. (See, e.g., Gee, J.E. et al. (1994) in Huber, B.E. and B.I. Carr, Molecular and Immunologic Approaches, Futura Publishing, Mt. Kisco NY, pp. 163-177.) A complementary sequence or antisense molecule may also be designed to block translation of mRNA by preventing the transcript from binding to ribosomes.

Ribozymes, enzymatic RNA molecules, may also be used to catalyze the specific cleavage of RNA. The mechanism of ribozyme action involves sequence-specific hybridization of the ribozyme molecule to complementary target RNA, followed by endonucleolytic cleavage. For

example, engineered hammerhead motif ribozyme molecules may specifically and efficiently catalyze endonucleolytic cleavage of sequences encoding CJPDPZ.

Specific ribozyme cleavage sites within any potential RNA target are initially identified by scanning the target molecule for ribozyme cleavage sites, including the following sequences:

- 5 GUA, GUU, and GUC. Once identified, short RNA sequences of between 15 and 20 ribonucleotides, corresponding to the region of the target gene containing the cleavage site, may be evaluated for secondary structural features which may render the oligonucleotide inoperable. The suitability of candidate targets may also be evaluated by testing accessibility to hybridization with complementary oligonucleotides using ribonuclease protection assays.

- 10 Complementary ribonucleic acid molecules and ribozymes of the invention may be prepared by any method known in the art for the synthesis of nucleic acid molecules. These include techniques for chemically synthesizing oligonucleotides such as solid phase phosphoramidite chemical synthesis. Alternatively, RNA molecules may be generated by in vitro and in vivo transcription of DNA sequences encoding CJPDPZ. Such DNA sequences may be  
15 incorporated into a wide variety of vectors with suitable RNA polymerase promoters such as T7 or SP6. Alternatively, these cDNA constructs that synthesize complementary RNA, constitutively or inducibly, can be introduced into cell lines, cells, or tissues.

- RNA molecules may be modified to increase intracellular stability and half-life. Possible modifications include, but are not limited to, the addition of flanking sequences at the 5' and/or 3'  
20 ends of the molecule, or the use of phosphorothioate or 2' O-methyl rather than phosphodiesterase linkages within the backbone of the molecule. This concept is inherent in the production of PNAs and can be extended in all of these molecules by the inclusion of nontraditional bases such as inosine, queosine, and wybutosine, as well as acetyl-, methyl-, thio-, and similarly modified forms of adenine, cytidine, guanine, thymine, and uridine which are not as easily recognized by  
25 endogenous endonucleases.

- Many methods for introducing vectors into cells or tissues are available and equally suitable for use in vivo, in vitro, and ex vivo. For ex vivo therapy, vectors may be introduced into stem cells taken from the patient and clonally propagated for autologous transplant back into that same patient. Delivery by transfection, by liposome injections, or by polycationic amino polymers  
30 may be achieved using methods which are well known in the art. (See, e.g., Goldman, C.K. et al. (1997) Nat. Biotechnol. 15:462-466.)

Any of the therapeutic methods described above may be applied to any subject in need of such therapy, including, for example, mammals such as dogs, cats, cows, horses, rabbits, monkeys, and most preferably, humans.



An additional embodiment of the invention relates to the administration of a pharmaceutical or sterile composition, in conjunction with a pharmaceutically acceptable carrier, for any of the therapeutic effects discussed above. Such pharmaceutical compositions may consist of CJPDZ, antibodies to CJPDZ, and mimetics, agonists, antagonists, or inhibitors of CJPDZ. The compositions may be administered alone or in combination with at least one other agent, such as a stabilizing compound, which may be administered in any sterile, biocompatible pharmaceutical carrier including, but not limited to, saline, buffered saline, dextrose, and water. The compositions may be administered to a patient alone, or in combination with other agents, drugs, or hormones.

The pharmaceutical compositions utilized in this invention may be administered by any number of routes including, but not limited to, oral, intravenous, intramuscular, intra-arterial, intramedullary, intrathecal, intraventricular, transdermal, subcutaneous, intraperitoneal, intranasal, enteral, topical, sublingual, or rectal means.

In addition to the active ingredients, these pharmaceutical compositions may contain suitable pharmaceutically-acceptable carriers comprising excipients and auxiliaries which facilitate processing of the active compounds into preparations which can be used pharmaceutically. Further details on techniques for formulation and administration may be found in the latest edition of Remington's Pharmaceutical Sciences (Maack Publishing, Easton PA).

Pharmaceutical compositions for oral administration can be formulated using pharmaceutically acceptable carriers well known in the art in dosages suitable for oral administration. Such carriers enable the pharmaceutical compositions to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions, and the like, for ingestion by the patient.

Pharmaceutical preparations for oral use can be obtained through combining active compounds with solid excipient and processing the resultant mixture of granules (optionally, after grinding) to obtain tablets or dragee cores. Suitable auxiliaries can be added, if desired. Suitable excipients include carbohydrate or protein fillers, such as sugars, including lactose, sucrose, mannitol, and sorbitol; starch from corn, wheat, rice, potato, or other plants; cellulose, such as methyl cellulose, hydroxypropylmethyl-cellulose, or sodium carboxymethylcellulose; gums, including arabic and tragacanth; and proteins, such as gelatin and collagen. If desired, disintegrating or solubilizing agents may be added, such as the cross-linked polyvinyl pyrrolidone, agar, and alginic acid or a salt thereof, such as sodium alginate.

Dragee cores may be used in conjunction with suitable coatings, such as concentrated sugar solutions, which may also contain gum arabic, talc, polyvinylpyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or

solvent mixtures. Dyestuffs or pigments may be added to the tablets or dragee coatings for product identification or to characterize the quantity of active compound, i.e., dosage.

Pharmaceutical preparations which can be used orally include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a coating, such as glycerol or sorbitol.

- 5 Push-fit capsules can contain active ingredients mixed with fillers or binders, such as lactose or starches, lubricants, such as talc or magnesium stearate, and, optionally, stabilizers. In soft capsules, the active compounds may be dissolved or suspended in suitable liquids, such as fatty oils, liquid, or liquid polyethylene glycol with or without stabilizers.

- Pharmaceutical formulations suitable for parenteral administration may be formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hanks' solution, Ringer's solution, or physiologically buffered saline. Aqueous injection suspensions may contain substances which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. Additionally, suspensions of the active compounds may be prepared as appropriate oily injection suspensions. Suitable lipophilic solvents or vehicles include
- 10 fatty oils, such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate, triglycerides, or liposomes. Non-lipid polycationic amino polymers may also be used for delivery. Optionally, the suspension may also contain suitable stabilizers or agents to increase the solubility of the compounds and allow for the preparation of highly concentrated solutions.

- For topical or nasal administration, penetrants appropriate to the particular barrier to be permeated are used in the formulation. Such penetrants are generally known in the art.
- 20

The pharmaceutical compositions of the present invention may be manufactured in a manner that is known in the art, e.g., by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping, or lyophilizing processes.

- The pharmaceutical composition may be provided as a salt and can be formed with many acids, including but not limited to, hydrochloric, sulfuric, acetic, lactic, tartaric, malic, and succinic acid. Salts tend to be more soluble in aqueous or other protonic solvents than are the corresponding free base forms. In other cases, the preferred preparation may be a lyophilized powder which may contain any or all of the following: 1 mM to 50 mM histidine, 0.1% to 2% sucrose, and 2% to 7% mannitol, at a pH range of 4.5 to 5.5, that is combined with buffer prior to
- 25
- 30 use.

After pharmaceutical compositions have been prepared, they can be placed in an appropriate container and labeled for treatment of an indicated condition. For administration of CJPDZ, such labeling would include amount, frequency, and method of administration.

Pharmaceutical compositions suitable for use in the invention include compositions

wherein the active ingredients are contained in an effective amount to achieve the intended purpose. The determination of an effective dose is well within the capability of those skilled in the art.

For any compound, the therapeutically effective dose can be estimated initially either in  
5 cell culture assays, e.g., of neoplastic cells or in animal models such as mice, rats, rabbits, dogs, or pigs. An animal model may also be used to determine the appropriate concentration range and route of administration. Such information can then be used to determine useful doses and routes for administration in humans.

A therapeutically effective dose refers to that amount of active ingredient, for example  
10 CJPDPZ or fragments thereof, antibodies of CJPDPZ, and agonists, antagonists or inhibitors of CJPDPZ, which ameliorates the symptoms or condition. Therapeutic efficacy and toxicity may be determined by standard pharmaceutical procedures in cell cultures or with experimental animals, such as by calculating the  $ED_{50}$  (the dose therapeutically effective in 50% of the population) or  $LD_{50}$  (the dose lethal to 50% of the population) statistics. The dose ratio of toxic to therapeutic  
15 effects is the therapeutic index, and it can be expressed as the  $LD_{50}/ED_{50}$  ratio. Pharmaceutical compositions which exhibit large therapeutic indices are preferred. The data obtained from cell culture assays and animal studies are used to formulate a range of dosage for human use. The dosage contained in such compositions is preferably within a range of circulating concentrations that includes the  $ED_{50}$  with little or no toxicity. The dosage varies within this range depending  
20 upon the dosage form employed, the sensitivity of the patient, and the route of administration.

The exact dosage will be determined by the practitioner, in light of factors related to the subject requiring treatment. Dosage and administration are adjusted to provide sufficient levels of the active moiety or to maintain the desired effect. Factors which may be taken into account include the severity of the disease state, the general health of the subject, the age, weight, and  
25 gender of the subject, time and frequency of administration, drug combination(s), reaction sensitivities, and response to therapy. Long-acting pharmaceutical compositions may be administered every 3 to 4 days, every week, or biweekly depending on the half-life and clearance rate of the particular formulation.

Normal dosage amounts may vary from about 0.1  $\mu$ g to 100,000  $\mu$ g, up to a total dose of  
30 about 1 gram, depending upon the route of administration. Guidance as to particular dosages and methods of delivery is provided in the literature and generally available to practitioners in the art. Those skilled in the art will employ different formulations for nucleotides than for proteins or their inhibitors. Similarly, delivery of polynucleotides or polypeptides will be specific to particular cells, conditions, locations, etc.

**DIAGNOSTICS**

In another embodiment, antibodies which specifically bind CJPDPZ may be used for the diagnosis of disorders characterized by expression of CJPDPZ, or in assays to monitor patients being treated with CJPDPZ or agonists, antagonists, or inhibitors of CJPDPZ. Antibodies useful for  
5 diagnostic purposes may be prepared in the same manner as described above for therapeutics. Diagnostic assays for CJPDPZ include methods which utilize the antibody and a label to detect CJPDPZ in human body fluids or in extracts of cells or tissues. The antibodies may be used with or without modification, and may be labeled by covalent or non-covalent attachment of a reporter molecule. A wide variety of reporter molecules, several of which are described above, are known  
10 in the art and may be used.

A variety of protocols for measuring CJPDPZ, including ELISAs, RIAs, and FACS, are known in the art and provide a basis for diagnosing altered or abnormal levels of CJPDPZ expression. Normal or standard values for CJPDPZ expression are established by combining body fluids or cell extracts taken from normal mammalian subjects, preferably human, with antibody to  
15 CJPDPZ under conditions suitable for complex formation. The amount of standard complex formation may be quantitated by various methods, preferably by photometric means. Quantities of CJPDPZ expressed in subject, control, and disease samples from biopsied tissues are compared with the standard values. Deviation between standard and subject values establishes the parameters for diagnosing disease.

In another embodiment of the invention, the polynucleotides encoding CJPDPZ may be used for diagnostic purposes. The polynucleotides which may be used include oligonucleotide sequences, complementary RNA and DNA molecules, and PNAs. The polynucleotides may be used to detect and quantitate gene expression in biopsied tissues in which expression of CJPDPZ may be correlated with disease. The diagnostic assay may be used to determine absence,  
20 presence, and excess expression of CJPDPZ, and to monitor regulation of CJPDPZ levels during therapeutic intervention.

In one aspect, hybridization with PCR probes which are capable of detecting polynucleotide sequences, including genomic sequences, encoding CJPDPZ or closely related molecules may be used to identify nucleic acid sequences which encode CJPDPZ. The specificity  
30 of the probe, whether it is made from a highly specific region, e.g., the 5' regulatory region, or from a less specific region, e.g., a conserved motif, and the stringency of the hybridization or amplification (maximal, high, intermediate, or low), will determine whether the probe identifies only naturally occurring sequences encoding CJPDPZ, allelic variants, or related sequences.

Probes may also be used for the detection of related sequences, and should preferably

have at least 50% sequence identity to any of the CJPDZ encoding sequences. The hybridization probes of the subject invention may be DNA or RNA and may be derived from the sequence of SEQ ID NO:2 or from genomic sequences including promoters, enhancers, and introns of the CJPDZ gene.

- 5 Means for producing specific hybridization probes for DNAs encoding CJPDZ include the cloning of polynucleotide sequences encoding CJPDZ or CJPDZ derivatives into vectors for the production of mRNA probes. Such vectors are known in the art, are commercially available, and may be used to synthesize RNA probes in vitro by means of the addition of the appropriate RNA polymerases and the appropriate labeled nucleotides. Hybridization probes may be labeled by a
- 10 variety of reporter groups, for example, by radionuclides such as  $^{32}\text{P}$  or  $^{35}\text{S}$ , or by enzymatic labels, such as alkaline phosphatase coupled to the probe via avidin/biotin coupling systems, and the like.

- Polynucleotide sequences encoding CJPDZ may be used for the diagnosis of disorders associated with expression of CJPDZ. Examples of such disorders include, but are not limited to, cancers such as adenocarcinoma, leukemia, lymphoma, melanoma, myeloma, sarcoma,
- 15 teratocarcinoma, and, in particular, cancers of the adrenal gland, bladder, bone, bone marrow, brain, breast, cervix, gall bladder, ganglia, gastrointestinal tract, heart, kidney, liver, lung, muscle, ovary, pancreas, parathyroid, penis, prostate, salivary glands, skin, spleen, testis, thymus, thyroid, and uterus; neurological disorders such as epilepsy, ischemic cerebrovascular disease, stroke, cerebral neoplasms, Alzheimer's disease, Pick's disease, Huntington's disease, dementia,
- 20 Parkinson's disease and other extrapyramidal disorders, amyotrophic lateral sclerosis and other motor neuron disorders, progressive neural muscular atrophy, retinitis pigmentosa, hereditary ataxias, multiple sclerosis and other demyelinating diseases, bacterial and viral meningitis, brain abscess, subdural empyema, epidural abscess, suppurative intracranial thrombophlebitis, myelitis and radiculitis, viral central nervous system disease, prion diseases including kuru,
- 25 Creutzfeldt-Jakob disease, and Gerstmann-Straussler-Scheinker syndrome, fatal familial insomnia, nutritional and metabolic diseases of the nervous system, neurofibromatosis, tuberous sclerosis, cerebelloretinal hemangioblastomatosis, encephalotrigeminal syndrome, mental retardation and other developmental disorders of the central nervous system, cerebral palsy, neuroskeletal disorders, autonomic nervous system disorders, cranial nerve disorders, spinal cord diseases,
- 30 muscular dystrophy and other neuromuscular disorders, peripheral nervous system disorders, dermatomyositis and polymyositis, inherited, metabolic, endocrine, and toxic myopathies, myasthenia gravis, periodic paralysis, mental disorders including mood, anxiety, and schizophrenic disorders, akathisia, amnesia, catatonia, diabetic neuropathy, tardive dyskinesia, dystonias, paranoid psychoses, postherpetic neuralgia, and Tourette's disorder; and developmental

disorders such as renal tubular acidosis, anemia, Cushing's syndrome, achondroplastic dwarfism, Duchenne and Becker muscular dystrophy, epilepsy, gonadal dysgenesis, WAGR syndrome (Wilms' tumor, aniridia, genitourinary abnormalities, and mental retardation), Smith-Magenis syndrome, myelodysplastic syndrome, hereditary mucoepithelial dysplasia, hereditary

5 keratodermas, hereditary neuropathies such as Charcot-Marie-Tooth disease and neurofibromatosis, hypothyroidism, hydrocephalus, seizure disorders such as Sydenham's chorea and cerebral palsy, spina bifida, Williams syndrome, anencephaly, craniorachischisis, congenital glaucoma, cataract, sensorineural hearing loss, and any disorder associated with cell growth and differentiation, embryogenesis, and morphogenesis involving any tissue, organ, or system of a

10 subject, e.g., the brain, adrenal gland, kidney, skeletal or reproductive system. The polynucleotide sequences encoding CJPZ may be used in Southern or northern analysis, dot blot, or other membrane-based technologies; in PCR technologies; in dipstick, pin, and multiformat ELISA-like assays; and in microarrays utilizing fluids or tissues from patients to detect altered CJPZ expression. Such qualitative or quantitative methods are well known in the art.

15 In a particular aspect, the nucleotide sequences encoding CJPZ may be useful in assays that detect the presence of associated disorders, particularly those mentioned above. The nucleotide sequences encoding CJPZ may be labeled by standard methods and added to a fluid or tissue sample from a patient under conditions suitable for the formation of hybridization complexes. After a suitable incubation period, the sample is washed and the signal is quantitated

20 and compared with a standard value. If the amount of signal in the patient sample is significantly altered in comparison to a control sample then the presence of altered levels of nucleotide sequences encoding CJPZ in the sample indicates the presence of the associated disorder. Such assays may also be used to evaluate the efficacy of a particular therapeutic treatment regimen in animal studies, in clinical trials, or to monitor the treatment of an individual patient.

25 In order to provide a basis for the diagnosis of a disorder associated with expression of CJPZ, a normal or standard profile for expression is established. This may be accomplished by combining body fluids or cell extracts taken from normal subjects, either animal or human, with a sequence, or a fragment thereof, encoding CJPZ, under conditions suitable for hybridization or amplification. Standard hybridization may be quantified by comparing the values obtained from

30 normal subjects with values from an experiment in which a known amount of a substantially purified polynucleotide is used. Standard values obtained in this manner may be compared with values obtained from samples from patients who are symptomatic for a disorder. Deviation from standard values is used to establish the presence of a disorder.

Once the presence of a disorder is established and a treatment protocol is initiated,

hybridization assays may be repeated on a regular basis to determine if the level of expression in the patient begins to approximate that which is observed in the normal subject. The results obtained from successive assays may be used to show the efficacy of treatment over a period ranging from several days to months.

5           With respect to cancer, the presence of an abnormal amount of transcript (either under- or over-expressed) in biopsied tissue from an individual may indicate a predisposition for the development of the disease, or may provide a means for detecting the disease prior to the appearance of actual clinical symptoms. A more definitive diagnosis of this type may allow health professionals to employ preventative measures or aggressive treatment earlier thereby preventing  
10 the development or further progression of the cancer.

Additional diagnostic uses for oligonucleotides designed from the sequences encoding CJPZ may involve the use of PCR. These oligomers may be chemically synthesized, generated enzymatically, or produced in vitro. Oligomers will preferably contain a fragment of a polynucleotide encoding CJPZ, or a fragment of a polynucleotide complementary to the  
15 polynucleotide encoding CJPZ, and will be employed under optimized conditions for identification of a specific gene or condition. Oligomers may also be employed under less stringent conditions for detection or quantitation of closely related DNA or RNA sequences.

Methods which may also be used to quantitate the expression of CJPZ include radiolabeling or biotinylating nucleotides, coamplification of a control nucleic acid, and  
20 interpolating results from standard curves. (See, e.g., Melby, P.C. et al. (1993) J. Immunol. Methods 159:235-244; Duplaa, C. et al. (1993) Anal. Biochem. 212:229-236.) The speed of quantitation of multiple samples may be accelerated by running the assay in an ELISA format where the oligomer of interest is presented in various dilutions and a spectrophotometric or colorimetric response gives rapid quantitation.

25           In further embodiments, oligonucleotides or longer fragments derived from any of the polynucleotide sequences described herein may be used as targets in a microarray. The microarray can be used to monitor the expression level of large numbers of genes simultaneously and to identify genetic variants, mutations, and polymorphisms. This information may be used to determine gene function, to understand the genetic basis of a disorder, to diagnose a disorder, and  
30 to develop and monitor the activities of therapeutic agents.

Microarrays may be prepared, used, and analyzed using methods known in the art. (See, e.g., Brennan, T.M. et al. (1995) U.S. Patent No. 5,474,796; Schena, M. et al. (1996) Proc. Natl. Acad. Sci. USA 93:10614-10619; Baldeschweiler et al. (1995) PCT application WO95/251116; Shalon, D. et al. (1995) PCT application WO95/35505; Heller, R.A. et al. (1997) Proc. Natl. Acad.

Sci. USA 94:2150-2155; and Heller, M.J. et al. (1997) U.S. Patent No. 5,605,662.)

In another embodiment of the invention, nucleic acid sequences encoding CJPZ may be used to generate hybridization probes useful in mapping the naturally occurring genomic sequence. The sequences may be mapped to a particular chromosome, to a specific region of a chromosome, or to artificial chromosome constructions, e.g., human artificial chromosomes (HACs), yeast artificial chromosomes (YACs), bacterial artificial chromosomes (BACs), bacterial P1 constructions, or single chromosome cDNA libraries. (See, e.g., Harrington, J.J. et al. (1997) Nat. Genet. 15:345-355; Price, C.M. (1993) Blood Rev. 7:127-134; and Trask, B.J. (1991) Trends Genet. 7:149-154.)

Fluorescent in situ hybridization (FISH) may be correlated with other physical chromosome mapping techniques and genetic map data. (See, e.g., Heinz-Ulrich, et al. (1995) in Meyers, supra, pp. 965-968.) Examples of genetic map data can be found in various scientific journals or at the Online Mendelian Inheritance in Man (OMIM) site. Correlation between the location of the gene encoding CJPZ on a physical chromosomal map and a specific disorder, or a predisposition to a specific disorder, may help define the region of DNA associated with that disorder. The nucleotide sequences of the invention may be used to detect differences in gene sequences among normal, carrier, and affected individuals.

In situ hybridization of chromosomal preparations and physical mapping techniques, such as linkage analysis using established chromosomal markers, may be used for extending genetic maps. Often the placement of a gene on the chromosome of another mammalian species, such as mouse, may reveal associated markers even if the number or arm of a particular human chromosome is not known. New sequences can be assigned to chromosomal arms by physical mapping. This provides valuable information to investigators searching for disease genes using positional cloning or other gene discovery techniques. Once the disease or syndrome has been crudely localized by genetic linkage to a particular genomic region, e.g., ataxia-telangiectasia to 11q22-23, any sequences mapping to that area may represent associated or regulatory genes for further investigation. (See, e.g., Gatti, R.A. et al. (1988) Nature 336:577-580.) The nucleotide sequence of the subject invention may also be used to detect differences in the chromosomal location due to translocation, inversion, etc., among normal, carrier, or affected individuals.

In another embodiment of the invention, CJPZ, its catalytic or immunogenic fragments, or oligopeptides thereof can be used for screening libraries of compounds in any of a variety of drug screening techniques. The fragment employed in such screening may be free in solution, affixed to a solid support, borne on a cell surface, or located intracellularly. The formation of binding complexes between CJPZ and the agent being tested may be measured.



Another technique for drug screening provides for high throughput screening of compounds having suitable binding affinity to the protein of interest. (See, e.g., Geysen, et al. (1984) PCT application WO84/03564.) In this method, large numbers of different small test compounds are synthesized on a solid substrate. The test compounds are reacted with CJPDPZ, or fragments thereof, and washed. Bound CJPDPZ is then detected by methods well known in the art. Purified CJPDPZ can also be coated directly onto plates for use in the aforementioned drug screening techniques. Alternatively, non-neutralizing antibodies can be used to capture the peptide and immobilize it on a solid support.

In another embodiment, one may use competitive drug screening assays in which neutralizing antibodies capable of binding CJPDPZ specifically compete with a test compound for binding CJPDPZ. In this manner, antibodies can be used to detect the presence of any peptide which shares one or more antigenic determinants with CJPDPZ.

In additional embodiments, the nucleotide sequences which encode CJPDPZ may be used in any molecular biology techniques that have yet to be developed, provided the new techniques rely on properties of nucleotide sequences that are currently known, including, but not limited to, such properties as the triplet genetic code and specific base pair interactions.

Without further elaboration, it is believed that one skilled in the art can, using the preceding description, utilize the present invention to its fullest extent. The following preferred specific embodiments are, therefore, to be construed as merely illustrative, and not limitative of the remainder of the disclosure in any way whatsoever.

The disclosures of all patents, applications, and publications mentioned above and below, in particular U.S. Ser. No. 09/151,611, are hereby expressly incorporated by reference.

## EXAMPLES

### I. cDNA Library Construction

The UCMCL5T01 cDNA library was constructed using RNA isolated from mononuclear cells obtained from umbilical cord blood of 12 individuals. The cells were cultured for 12 days in the presence of IL-5 prior to RNA isolation from the pooled lysates.

Cells were homogenized and lysed in guanidinium isothiocyanate solution using a Brinkmann Homogenizer Polytron PT-3000 (Brinkmann Instruments, Westbury NY). The lysate was centrifuged over a CsCl cushion to isolate RNA. The RNA was extracted with acid phenol, precipitated with sodium acetate and ethanol, resuspended in RNase-free water, and treated with DNase. Poly(A<sup>+</sup>) RNA was isolated using the OLIGOTEX mRNA purification kit (QIAGEN,

Chatsworth CA).

Poly(A<sup>+</sup>) RNA was used for cDNA synthesis and construction of the cDNA library according to the recommended protocols in the SUPERScript plasmid system (Life Technologies). The cDNAs were fractionated on a SEPHAROSE CL4B column (Amersham Pharmacia Biotech), and those cDNAs exceeding 400 bp were ligated into pINCY (Incyte Pharmaceuticals, Palo Alto CA). Recombinant plasmids were transformed into DH5 $\alpha$  competent cells (Life Technologies).

## II. Isolation of cDNA Clones

Plasmid DNA was released from the cells and purified using the REAL Prep 96 plasmid kit (QIAGEN). The recommended protocol was employed except for the following changes: 1) the bacteria were cultured in 1 ml of sterile Terrific Broth (Life Technologies) with carbenicillin at 25 mg/l and glycerol at 0.4%; 2) after the cultures were incubated for 19 hours, the cells were lysed with 0.3 ml of lysis buffer; and 3) following isopropanol precipitation, the plasmid DNA pellets were each resuspended in 0.1 ml of distilled water. The DNA samples were stored at 4°C.

## III. Sequencing and Analysis

The cDNAs were prepared for sequencing using the ABI CATALYST 800 (Perkin-Elmer) or the HYDRA microdispenser (Robbins Scientific) or MICROLAB 2200 (Hamilton) systems in combination with the PTC-200 thermal cyclers (MJ Research). The cDNAs were sequenced using the ABI PRISM 373 or 377 sequencing systems (Perkin-Elmer) and standard ABI protocols, base calling software, and kits. In one alternative, cDNAs were sequenced using the MEGABACE 1000 DNA sequencing system (Molecular Dynamics). In another alternative, the cDNAs were amplified and sequenced using the ABI PRISM BIGDYE Terminator cycle sequencing ready reaction kit (Perkin-Elmer). In yet another alternative, cDNAs were sequenced using solutions and dyes from Amersham Pharmacia Biotech. Reading frames for the ESTs were determined using standard methods (reviewed in Ausubel, 1997, *supra*, unit 7.7). Some of the cDNA sequences were selected for extension using the techniques disclosed in Example V.

The polynucleotide sequences derived from cDNA, extension, and shotgun sequencing were assembled and analyzed using a combination of software programs which utilize algorithms well known to those skilled in the art. Table 1 summarizes the software programs, descriptions, references, and threshold parameters used. The first column of Table 1 shows the tools, programs, and algorithms used, the second column provides a brief description thereof, the third column presents the references which are incorporated by reference herein, and the fourth column presents, where applicable, the scores, probability values, and other parameters used to evaluate the strength of a match between two sequences (the higher the probability the greater the

homology). Sequences were analyzed using MACDNASIS PRO software (Hitachi Software Engineering) and LASERGENE software (DNASTAR).

The polynucleotide sequences were validated by removing vector, linker, and polyA sequences and by masking ambiguous bases, using algorithms and programs based on BLAST, dynamic programming, and dinucleotide nearest neighbor analysis. The sequences were then queried against a selection of public databases such as GenBank primate, rodent, mammalian, vertebrate, and eukaryote databases, and BLOCKS to acquire annotation, using programs based on BLAST, FASTA, and BLIMPS. The sequences were assembled into full length polynucleotide sequences using programs based on Phred, Phrap, and Consed, and were screened for open reading frames using programs based on GeneMark, BLAST, and FASTA. The full length polynucleotide sequences were translated to derive the corresponding full length amino acid sequences, and these full length sequences were subsequently analyzed by querying against databases such as the GenBank databases (described above), SwissProt, BLOCKS, PRINTS, PFAM, and Prosite.

The programs described above for the assembly and analysis of full length polynucleotide and amino acid sequences were used to identify polynucleotide sequence fragments from SEQ ID NO:2. Fragments from about 20 to about 4000 nucleotides which are useful in hybridization and amplification technologies were described in The Invention section above.

#### IV. Northern Analysis

Northern analysis is a laboratory technique used to detect the presence of a transcript of a gene and involves the hybridization of a labeled nucleotide sequence to a membrane on which RNAs from a particular cell type or tissue have been bound. (See, e.g., Sambrook, *supra*, ch. 7; Ausubel, 1995, *supra*, ch. 4 and 16.)

Analogous computer techniques applying BLAST were used to search for identical or related molecules in nucleotide databases such as GenBank or LIFESEQ database (Incyte Pharmaceuticals, Palo Alto CA). This analysis is much faster than multiple membrane-based hybridizations. In addition, the sensitivity of the computer search can be modified to determine whether any particular match is categorized as exact or similar. The basis of the search is the product score, which is defined as:

$$\frac{\% \text{ sequence identity} \times \% \text{ maximum BLAST score}}{100}$$

100

The product score takes into account both the degree of similarity between two sequences and the length of the sequence match. For example, with a product score of 40, the match will be exact within a 1% to 2% error, and, with a product score of 70, the match will be exact. Similar

molecules are usually identified by selecting those which show product scores between 15 and 40, although lower scores may identify related molecules.

The results of northern analyses are reported a percentage distribution of libraries in which the transcript encoding CJPDZ occurred. Analysis involved the categorization of cDNA libraries by organ/tissue and disease. The organ/tissue categories included cardiovascular, dermatologic, developmental, endocrine, gastrointestinal, hematopoietic/immune, musculoskeletal, nervous, reproductive, and urologic. The disease categories included cancer, inflammation/trauma, fetal, neurological, and pooled. For each category, the number of libraries expressing the sequence of interest was counted and divided by the total number of libraries across all categories. Percentage values of tissue-specific and disease expression are reported in the description of the invention.

#### V. Extension of CJPDZ Encoding Polynucleotides

The full length nucleic acid sequence of SEQ ID NO:2 was produced by extension of an appropriate fragment of the full length molecule using oligonucleotide primers designed from this fragment. One primer was synthesized to initiate 5' extension of the known fragment, and the other primer, to initiate 3' extension of the known fragment. The initial primers were designed using OLIGO 4.06 software (National Biosciences), or another appropriate program, to be about 22 to 30 nucleotides in length, to have a GC content of about 50% or more, and to anneal to the target sequence at temperatures of about 68°C to about 72°C. Any stretch of nucleotides which would result in hairpin structures and primer-primer dimerizations was avoided.

Selected human cDNA libraries were used to extend the sequence. If more than one extension was necessary or desired, additional or nested sets of primers were designed.

High fidelity amplification was obtained by PCR using methods well known in the art. PCR was performed in 96-well plates using the PTC-200 thermal cycler (MJ Research, Inc.). The reaction mix contained DNA template, 200 nmol of each primer, reaction buffer containing  $Mg^{2+}$ ,  $(NH_4)_2SO_4$ , and  $\beta$ -mercaptoethanol, Taq DNA polymerase (Amersham Pharmacia Biotech), ELONGASE enzyme (Life Technologies), and Pfu DNA polymerase (Stratagene), with the following parameters for primer pair PCI A and PCI B: Step 1: 94°C, 3 min; Step 2: 94°C, 15 sec; Step 3: 60°C, 1 min; Step 4: 68°C, 2 min; Step 5: Steps 2, 3, and 4 repeated 20 times; Step 6: 68°C, 5 min; Step 7: storage at 4°C. In the alternative, the parameters for primer pair T7 and SK+ were as follows: Step 1: 94°C, 3 min; Step 2: 94°C, 15 sec; Step 3: 57°C, 1 min; Step 4: 68°C, 2 min; Step 5: Steps 2, 3, and 4 repeated 20 times; Step 6: 68°C, 5 min; Step 7: storage at 4°C.

The concentration of DNA in each well was determined by dispensing 100  $\mu$ l PICO GREEN quantitation reagent (0.25% (v/v) PICO GREEN; Molecular Probes, Eugene OR) dissolved in 1X TE and 0.5  $\mu$ l of undiluted PCR product into each well of an opaque fluorimeter

plate (Corning Costar, Acton MA), allowing the DNA to bind to the reagent. The plate was scanned in a Fluoroskan II (Labsystems Oy, Helsinki, Finland) to measure the fluorescence of the sample and to quantify the concentration of DNA. A 5  $\mu$ l to 10  $\mu$ l aliquot of the reaction mixture was analyzed by electrophoresis on a 1 % agarose mini-gel to determine which reactions were successful in extending the sequence.

The extended nucleotides were desalted and concentrated, transferred to 384-well plates, digested with CviJI cholera virus endonuclease (Molecular Biology Research, Madison WI), and sonicated or sheared prior to religation into pUC 18 vector (Amersham Pharmacia Biotech). For shotgun sequencing, the digested nucleotides were separated on low concentration (0.6 to 0.8%) agarose gels, fragments were excised, and agar digested with Agar ACE (Promega). Extended clones were religated using T4 ligase (New England Biolabs, Beverly MA) into pUC 18 vector (Amersham Pharmacia Biotech), treated with *Pfu* DNA polymerase (Stratagene) to fill-in restriction site overhangs, and transfected into competent *E. coli* cells. Transformed cells were selected on antibiotic-containing media, individual colonies were picked and cultured overnight at 37°C in 384-well plates in LB/2x carb liquid media.

The cells were lysed, and DNA was amplified by PCR using Taq DNA polymerase (Amersham Pharmacia Biotech) and Pfu DNA polymerase (Stratagene) with the following parameters: Step 1: 94°C, 3 min; Step 2: 94°C, 15 sec; Step 3: 60°C, 1 min; Step 4: 72°C, 2 min; Step 5: steps 2, 3, and 4 repeated 29 times; Step 6: 72°C, 5 min; Step 7: storage at 4°C. DNA was quantified by PICOGREEN reagent (Molecular Probes) as described above. Samples with low DNA recoveries were reamplified using the same conditions as described above. Samples were diluted with 20% dimethylsulphoxide (1:2, v/v), and sequenced using DYENAMIC energy transfer sequencing primers and the DYENAMIC DIRECT kit (Amersham Pharmacia Biotech) or the ABI PRISM BIGDYE Terminator cycle sequencing ready reaction kit (Perkin-Elmer).

In like manner, the nucleotide sequence of SEQ ID NO:2 is used to obtain 5' regulatory sequences using the procedure above, oligonucleotides designed for such extension, and an appropriate genomic library.

## **VI. Labeling and Use of Individual Hybridization Probes**

Hybridization probes derived from SEQ ID NO:2 are employed to screen cDNAs, genomic DNAs, or mRNAs. Although the labeling of oligonucleotides, consisting of about 20 base pairs, is specifically described, essentially the same procedure is used with larger nucleotide fragments. Oligonucleotides are designed using state-of-the-art software such as OLIGO 4.06 software (National Biosciences) and labeled by combining 50 pmol of each oligomer, 250  $\mu$ Ci of [<sup>32</sup>P]-adenosine triphosphate (Amersham Pharmacia Biotech), and T4 polynucleotide kinase

(DuPont NEN, Boston MA). The labeled oligonucleotides are substantially purified using a SEPHADEX G-25 superfine size exclusion dextran bead column (Amersham Pharmacia Biotech). An aliquot containing  $10^7$  counts per minute of the labeled probe is used in a typical membrane-based hybridization analysis of human genomic DNA digested with one of the following  
5 endonucleases: Ase I, Bgl II, Eco RI, Pst I, Xba I, or Pvu II (DuPont NEN).

The DNA from each digest is fractionated on a 0.7% agarose gel and transferred to nylon membranes (Nytran Plus, Schleicher & Schuell, Durham NH). Hybridization is carried out for 16 hours at 40°C. To remove nonspecific signals, blots are sequentially washed at room temperature under increasingly stringent conditions up to 0.1x saline sodium citrate and 0.5% sodium dodecyl  
10 sulfate. After XOMAT-AR film (Eastman Kodak, Rochester NY) is exposed to the blots to film for several hours, hybridization patterns are compared visually.

## VII. Microarrays

A chemical coupling procedure and an ink jet device can be used to synthesize array elements on the surface of a substrate. (See, e.g., Baldeschweiler, supra.) An array analogous to a  
15 dot or slot blot may also be used to arrange and link elements to the surface of a substrate using thermal, UV, chemical, or mechanical bonding procedures. A typical array may be produced by hand or using available methods and machines and contain any appropriate number of elements. After hybridization, nonhybridized probes are removed and a scanner used to determine the levels and patterns of fluorescence. The degree of complementarity and the relative abundance of each  
20 probe which hybridizes to an element on the microarray may be assessed through analysis of the scanned images.

Full-length cDNAs, Expressed Sequence Tags (ESTs), or fragments thereof may comprise the elements of the microarray. Fragments suitable for hybridization can be selected using software well known in the art such as LASERGENE software (DNASTAR). Full-length  
25 cDNAs, ESTs, or fragments thereof corresponding to one of the nucleotide sequences of the present invention, or selected at random from a cDNA library relevant to the present invention, are arranged on an appropriate substrate, e.g., a glass slide. The cDNA is fixed to the slide using, e.g., UV cross-linking followed by thermal and chemical treatments and subsequent drying. (See, e.g., Schena, M. et al. (1995) Science 270:467-470; Shalon, D. et al. (1996) Genome Res. 6:639-645.)  
30 Fluorescent probes are prepared and used for hybridization to the elements on the substrate. The substrate is analyzed by procedures described above.

## VIII. Complementary P lyonucleotides

Sequences complementary to the CJPZ-encoding sequences, or any parts thereof, are used to detect, decrease, or inhibit expression of naturally occurring CJPZ. Although use of

oligonucleotides comprising from about 15 to 30 base pairs is described, essentially the same procedure is used with smaller or with larger sequence fragments. Appropriate oligonucleotides are designed using OLIGO 4.06 software (National Biosciences) and the coding sequence of CJPDPZ. To inhibit transcription, a complementary oligonucleotide is designed from the most  
5 unique 5' sequence and used to prevent promoter binding to the coding sequence. To inhibit translation, a complementary oligonucleotide is designed to prevent ribosomal binding to the CJPDPZ-encoding transcript.

#### IX. Expression of CJPDPZ

Expression and purification of CJPDPZ are achieved using bacterial or virus-based  
10 expression systems. For expression of CJPDPZ in bacteria, cDNA is subcloned into an appropriate vector containing an antibiotic resistance gene and an inducible promoter that directs high levels of cDNA transcription. Examples of such promoters include, but are not limited to, the *trp-lac* (*lac*) hybrid promoter and the T5 or T7 bacteriophage promoter in conjunction with the *lac* operator regulatory element. Recombinant vectors are transformed into suitable bacterial hosts,  
15 e.g., BL21(DE3). Antibiotic resistant bacteria express CJPDPZ upon induction with isopropyl beta-D-thiogalactopyranoside (IPTG). Expression of CJPDPZ in eukaryotic cells is achieved by infecting insect or mammalian cell lines with recombinant Autographica californica nuclear polyhedrosis virus (AcMNPV), commonly known as baculovirus. The nonessential polyhedrin gene of baculovirus is replaced with cDNA encoding CJPDPZ by either homologous recombination  
20 or bacterial-mediated transposition involving transfer plasmid intermediates. Viral infectivity is maintained and the strong polyhedrin promoter drives high levels of cDNA transcription. Recombinant baculovirus is used to infect Spodoptera frugiperda (Sf9) insect cells in most cases, or human hepatocytes, in some cases. Infection of the latter requires additional genetic modifications to baculovirus. (See Engelhard, E.K. et al. (1994) Proc. Natl. Acad. Sci. USA  
25 91:3224-3227; Sandig, V. et al. (1996) Hum. Gene Ther. 7:1937-1945.)

In most expression systems, CJPDPZ is synthesized as a fusion protein with, e.g., glutathione S-transferase (GST) or a peptide epitope tag, such as FLAG or 6-His, permitting rapid, single-step, affinity-based purification of recombinant fusion protein from crude cell lysates. GST, a 26-kilodalton enzyme from Schistosoma japonicum, enables the purification of fusion  
30 proteins on immobilized glutathione under conditions that maintain protein activity and antigenicity (Amersham Pharmacia Biotech). Following purification, the GST moiety can be proteolytically cleaved from CJPDPZ at specifically engineered sites. FLAG, an 8-amino acid peptide, enables immunoaffinity purification using commercially available monoclonal and polyclonal anti-FLAG antibodies (Eastman Kodak). 6-His, a stretch of six consecutive histidine

residues, enables purification on metal-chelate resins (QIAGEN). Methods for protein expression and purification are discussed in Ausubel (1995, supra, ch 10 and 16). Purified CJPDZ obtained by these methods can be used directly in the following activity assay.

#### **X. Demonstration of CJPDZ Activity**

5 An assay for CJPDZ activity measures the PDZ-induced clustering of transmembrane receptors (Ponting, supra). Cultured cell lines are cotransfected with cDNA encoding CJPDZ and either EGF receptor or NMDA receptor. Control cell lines are transfected with only one of the above cDNAs. Clustering of EGF receptors or NMDA receptors in the cotransfected cell lines is detected and quantified using commercially available antibody specific to these receptors in  
10 conjunction with indirect immunofluorescence and image analysis systems. The amount of receptor clustering is directly proportional to the amount of CJPDZ activity.

#### **XI. Functional Assays**

CJPDZ function is assessed by expressing the sequences encoding CJPDZ at physiologically elevated levels in mammalian cell culture systems. cDNA is subcloned into a  
15 mammalian expression vector containing a strong promoter that drives high levels of cDNA expression. Vectors of choice include pCMV SPORT (Life Technologies) and pCR3.1 (Invitrogen, Carlsbad CA), both of which contain the cytomegalovirus promoter. 5-10 µg of recombinant vector are transiently transfected into a human cell line, preferably of endothelial or hematopoietic origin, using either liposome formulations or electroporation. 1-2 µg of an  
20 additional plasmid containing sequences encoding a marker protein are co-transfected. Expression of a marker protein provides a means to distinguish transfected cells from nontransfected cells and is a reliable predictor of cDNA expression from the recombinant vector. Marker proteins of choice include, e.g., Green Fluorescent Protein (GFP; Clontech), CD64, or a CD64-GFP fusion protein. Flow cytometry (FCM), an automated, laser optics-based technique, is used to identify  
25 transfected cells expressing GFP or CD64-GFP, and to evaluate cellular properties, for example, their apoptotic state. FCM detects and quantifies the uptake of fluorescent molecules that diagnose events preceding or coincident with cell death. These events include changes in nuclear DNA content as measured by staining of DNA with propidium iodide; changes in cell size and granularity as measured by forward light scatter and 90 degree side light scatter; down-regulation  
30 of DNA synthesis as measured by decrease in bromodeoxyuridine uptake; alterations in expression of cell surface and intracellular proteins as measured by reactivity with specific antibodies; and alterations in plasma membrane composition as measured by the binding of fluorescein-conjugated Annexin V protein to the cell surface. Methods in flow cytometry are discussed in Ormerod, M.G. (1994) Flow Cytometry, Oxford, New York NY.



The influence of CJPDZ on gene expression can be assessed using highly purified populations of cells transfected with sequences encoding CJPDZ and either CD64 or CD64-GFP. CD64 and CD64-GFP are expressed on the surface of transfected cells and bind to conserved regions of human immunoglobulin G (IgG). Transfected cells are efficiently separated from nontransfected cells using magnetic beads coated with either human IgG or antibody against CD64 (DYNAL, Lake Success NY). mRNA can be purified from the cells using methods well known by those of skill in the art. Expression of mRNA encoding CJPDZ and other genes of interest can be analyzed by northern analysis or microarray techniques.

## **XII. Production of CJPDZ Specific Antibodies**

CJPDZ substantially purified using polyacrylamide gel electrophoresis (PAGE; see, e.g., Harrington, M.G. (1990) *Methods Enzymol.* 182:488-495), or other purification techniques, is used to immunize rabbits and to produce antibodies using standard protocols.

Alternatively, the CJPDZ amino acid sequence is analyzed using LASERGENE software (DNASTAR) to determine regions of high immunogenicity, and a corresponding oligopeptide is synthesized and used to raise antibodies by means known to those of skill in the art. Methods for selection of appropriate epitopes, such as those near the C-terminus or in hydrophilic regions are well described in the art. (See, e.g., Ausubel, 1995, *supra*, ch. 11.)

Typically, oligopeptides 15 residues in length are synthesized using an ABI 431A Peptide Synthesizer (Perkin-Elmer) using fmoc-chemistry and coupled to KLH (Sigma-Aldrich, St. Louis MO) by reaction with N-maleimidobenzoyl-N-hydroxysuccinimide ester (MBS) to increase immunogenicity. (See, e.g., Ausubel, 1995, *supra*.) Rabbits are immunized with the oligopeptide-KLH complex in complete Freund's adjuvant. Resulting antisera are tested for antipeptide activity by, for example, binding the peptide to plastic, blocking with 1% BSA, reacting with rabbit antisera, washing, and reacting with radio-iodinated goat anti-rabbit IgG.

## **XIII. Purification of Naturally Occurring CJPDZ Using Specific Antibodies**

Naturally occurring or recombinant CJPDZ is substantially purified by immunoaffinity chromatography using antibodies specific for CJPDZ. An immunoaffinity column is constructed by covalently coupling anti-CJPDZ antibody to an activated chromatographic resin, such as CNBr-activated SEPHAROSE (Amersham Pharmacia Biotech). After the coupling, the resin is blocked and washed according to the manufacturer's instructions.

Media containing CJPDZ are passed over the immunoaffinity column, and the column is washed under conditions that allow the preferential absorbance of CJPDZ (e.g., high ionic strength buffers in the presence of detergent). The column is eluted under conditions that disrupt antibody/CJPDZ binding (e.g., a buffer of pH 2 to pH 3, or a high concentration of a chaotrope,

such as urea or thiocyanate ion), and CJPZ is collected.

#### **XIV. Identification of Molecules Which Interact with CJPZ**

CJPZ, or biologically active fragments thereof, are labeled with <sup>125</sup>I Bolton-Hunter reagent. (See, e.g., Bolton, A.E. and W.M. Hunter (1973) Biochem. J. 133:529-539.) Candidate  
5 molecules previously arrayed in the wells of a multi-well plate are incubated with the labeled CJPZ, washed, and any wells with labeled CJPZ complex are assayed. Data obtained using different concentrations of CJPZ are used to calculate values for the number, affinity, and association of CJPZ with the candidate molecules.

- 10 Various modifications and variations of the described methods and systems of the invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection with specific preferred  
embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying  
15 out the invention which are obvious to those skilled in molecular biology or related fields are intended to be within the scope of the following claims.

Table 1

Program	Description	Reference	Parameter Threshold
ABI FACTURA	A program that removes vector sequences and masks ambiguous bases in nucleic acid sequences.	Perkin-Elmer Applied Biosystems, Foster City, CA.	
ABI/PARACEL FDF	A Fast Data Finder useful in comparing and annotating amino acid or nucleic acid sequences.	Perkin-Elmer Applied Biosystems, Foster City, CA; Paracel Inc., Pasadena, CA.	Mismatch <50%
ABI AutoAssembler	A program that assembles nucleic acid sequences.	Perkin-Elmer Applied Biosystems, Foster City, CA.	
BLAST	A Basic Local Alignment Search Tool useful in sequence similarity search for amino acid and nucleic acid sequences. BLAST includes five functions: blastp, blastn, blastx, tblastn, and tblastx.	Altschul, S.F. et al. (1990) J. Mol. Biol. 215:403-410; Altschul, S.F. et al. (1997) Nucleic Acids Res. 25: 3389-3402.	ESTs: Probability value= 1.0E-8 or less Full Length sequences: Probability value= 1.0E-10 or less
FASTA	A Pearson and Lipman algorithm that searches for similarity between a query sequence and a group of sequences of the same type. FASTA comprises at least five functions: fasta, ifasta, fastx, ifastx, and ssearch.	Pearson, W.R. and D.J. Lipman (1988) Proc. Natl. Acad. Sci. 85:2444-2448; Pearson, W.R. (1990) Methods Enzymol. 183: 63-98; and Smith, T.F. and M. S. Waterman (1981) Adv. Appl. Math. 2:482-489.	ESTs: fasta E value=1.0E-6 Assembled ESTs: fasta Identity= 95% or greater and Match length=200 bases or greater; fastx E value= 1.0E-8 or less Full Length sequences: fastx score=100 or greater
BLIMPS	A BLocks IMProved Searcher that matches a sequence against those in BLOCKS and PRINTS databases to search for gene families, sequence homology, and structural fingerprint regions.	Henikoff, S and J.G. Henikoff, Nucl. Acid Res. 19:6565-72, 1991. J.G. Henikoff and S. Henikoff (1996) Methods Enzymol. 266:88-105; and Attwood, T.K. et al. (1997) J. Chem. Inf. Comput. Sci. 37: 417-424.	Score=1000 or greater; Ratio of Score/Strength = 0.75 or larger; and Probability value= 1.0E-3 or less
PFAM	A Hidden Markov Models-based application useful for protein family search.	Krogh, A. et al. (1994) J. Mol. Biol. 235:1501-1531; Sonnhammer, E.L.L. et al. (1988) Nucleic Acids Res. 26:320-322.	Score=10-50 bits, depending on individual protein families

Table 1 cont.

Program	Description	Reference	Parameter Threshold
ProfileScan	An algorithm that searches for structural and sequence motifs in protein sequences that match sequence patterns defined in Prosite.	Gribskov, M. et al. (1988) CABIOS 4:61-66; Gribskov, et al. (1989) Methods Enzymol. 183:146-159; Bairoch, A. et al. (1997) Nucleic Acids Res. 25: 217-221.	Score= 4.0 or greater
Phred	A base-calling algorithm that examines automated sequencer traces with high sensitivity and probability.	Ewing, B. et al. (1998) Genome Res. 8:175-185; Ewing, B. and P. Green (1998) Genome Res. 8:186-194.	
Phrap	A Phils Revised Assembly Program including SWAT and CrossMatch, programs based on efficient implementation of the Smith-Waterman algorithm, useful in searching sequence homology and assembling DNA sequences.	Smith, T.F. and M. S. Waterman (1981) Adv. Appl. Math. 2:482-489; Smith, T.F. and M. S. Waterman (1981) J. Mol. Biol. 147:195-197; and Green, P., University of Washington, Seattle, WA.	Score= 120 or greater; Match length= 56 or greater
Consed	A graphical tool for viewing and editing Phrap assemblies	Gordon, D. et al. (1998) Genome Res. 8:195-202.	
SPScan	A weight matrix analysis program that scans protein sequences for the presence of secretory signal peptides.	Nielson, H. et al. (1997) Protein Engineering 10:1-6; Claverie, J.M. and S. Audic (1997) CABIOS 12: 431-439.	Score=5 or greater
Motifs	A program that searches amino acid sequences for patterns that matched those defined in Prosite.	Bairoch et al. <i>supra</i> ; Wisconsin Package Program Manual, version 9, page M51-59, Genetics Computer Group, Madison, WI.	

What is claimed is:

1. A substantially purified polypeptide comprising the amino acid sequence of SEQ ID NO:1 or a fragment thereof.
- 5       2. A substantially purified variant having at least 90% amino acid sequence identity to the amino acid sequence of claim 1.
3. An isolated and purified polynucleotide encoding the polypeptide of claim 1.
4. An isolated and purified polynucleotide variant having at least 90% polynucleotide sequence identity to the polynucleotide of claim 3.
- 10       5. An isolated and purified polynucleotide which hybridizes under stringent conditions to the polynucleotide of claim 3.
6. An isolated and purified polynucleotide having a sequence which is complementary to the polynucleotide of claim 3.
7. A method for detecting a polynucleotide, the method comprising the steps of:
  - 15       (a) hybridizing the polynucleotide of claim 6 to at least one nucleic acid in a sample, thereby forming a hybridization complex; and
  - (b) detecting the hybridization complex, wherein the presence of the hybridization complex correlates with the presence of the polynucleotide in the sample.
8. The method of claim 7 further comprising amplifying the polynucleotide prior to  
20   hybridization.
9. An isolated and purified polynucleotide comprising the polynucleotide sequence of SEQ ID NO:2 or a fragment thereof.
10. An isolated and purified polynucleotide variant having at least 90% polynucleotide sequence identity to the polynucleotide of claim 9.
- 25       11. An isolated and purified polynucleotide having a sequence which is complementary to the polynucleotide of claim 9.
12. An expression vector comprising at least a fragment of the polynucleotide of claim 3.
13. A host cell comprising the expression vector of claim 12.
14. A method for producing a polypeptide, the method comprising the steps of:
  - 30       (a) culturing the host cell of claim 13 under conditions suitable for the expression of the polypeptide; and
  - (b) recovering the polypeptide from the host cell culture.
15. A pharmaceutical composition comprising the polypeptide of claim 1 in conjunction with a suitable pharmaceutical carrier.

16. A purified antibody which specifically binds to the polypeptide of claim 1.
17. A purified agonist of the polypeptide of claim 1.
18. A purified antagonist of the polypeptide of claim 1.
19. A method for treating or preventing a disorder associated with decreased expression  
5 or activity of CJPDPZ, the method comprising administering to a subject in need of such treatment  
an effective amount of the pharmaceutical composition of claim 15.
20. A method for treating or preventing a disorder associated with increased expression or  
activity of CJPDPZ, the method comprising administering to a subject in need of such treatment an  
effective amount of the antagonist of claim 18.

10

```

11  GAGGC AAG AAT TCG GCA CGA GGC TCA GCT CCG CAC CGC AAC TGA AGA TCT GCC GCC 56
5'
65  GCG GAA CAG TTG CGT CTC CAT CTG GCT ACC AAC CCA CCC AAG CTT TCT TCT CCA 110
119 CCA CCA CCA CCT TCC TTC CTT CCC CCT CCT CCC CCT TTC GGT CCT CCC TCT 164
173 CCA CCC CCG CCC CCA ATC TCC TCC TTT TTT TCT CAC TAC GAG CGG TTG CTG ATG 218
      M
227 CTG AAG CCG AGC GTC ACT TCG GCT CCC ACG GCA GAC ATG GCG ACA TTG ACA GTG 272
      L K P S V T S A P T A D M A T L T V
281 GTC CAG CCG CTC ACC CTG GAC AGA GAT GTT GCA AGA GCA ATT GAA TTA CTG GAA 326
      V Q P L T L D R D V A R A I E L L E
335 AAA CTA CAG GAA TCT GGA GAA GTA CCA CCA GTG CAC AAG CTA CAA TCC CTC AAA AAA 380
      K L Q E S G E V P P V H K L Q S L K K
389 GTG CTT CAG AGT GAG TTT TGT ACA GCT ATT CGA GAG GTG TAT CAA TAT ATG CAT 434
      V L Q S E F C T A I R E V Y Q Y M H

```

FIGURE 1A

443	442	441	440	439	488
GAA ACG ATA ACT GTT AAT GGC TGT CCC GAA TTC CGT GCA AGG GCA ACA GCA AAG					
E T I T V N G C P E F R A R A T A K					
497	506	515	524	533	542
GCA ACA GTT GCA GCT TTT GCA GCT AGT GAA GGC CAC TCC CAC CCT CGA GTA GTT					
A T V A A F A A S E G H S H P R V V					
551	560	569	578	587	596
GAA CTG CCA AAG ACT GAT GAA GGC CTT GGT TTT AAT GTG ATG GGA AAG GAG					
E L P K T D E G L G F N V M G K E					
605	614	623	632	641	650
CAA AAT TCC CCC ATT TAT ATC TCT CGC ATA ATT CCT GGA GGG GTG GCT GAA AGA					
Q N S P I Y I S R I I P G G V A E R					
659	668	677	686	695	704
CAC GGA GGC CTC AAA AGA GGA GAC CAG CTG CTA TCA TCA AAC GGA GTG AGT GTG					
H G G L K R G D Q L L S V N G V S V					
713	722	731	740	749	758
GAA GGA GAA CAC CAT GAG AAA GCT GTG GAA CTA CTC AAG GCT GCT AAA GAC AGC					
E G E H H E K A A V E L L K A A K D S					
767	776	785	794	803	812
GTC AAG CTG GTG GTG CGA TAC ACC CCA AAA GTT CTG GAA GAA ATG GAG GCT CGC					
V K L V V R Y T P K V L E E M E A R					

FIGURE 1B



821	830	839	848	857	866
TTT GAA AAG CTA CGA ACA GCC AGG CGT CGG CAG CAG CAA TTG CTA ATT CAG					
F E K L R T A R R R Q Q Q Q L I Q					
875	884	893	902	911	920
CAG CAG CAA CAG CAG CAG CAA CAA ACA CAA AAC CAC ATG TCA TAG GCC					
Q Q Q Q Q Q Q Q T Q Q N H M S					
929	938	947	956	965	974
CTT GAG GGA AAG CTA CTT GAT CAA ACA TCC GAT AGT CAC AAA TTT GAA ACC GTG					
983	992	1001	1010	1019	1028
CTT CAG AAT CCC AGC ACA TAG TAA AAG ACA ACA CTG ATA ATT ATA CCT GTC AAG					
1037	1046	1055	1064	1073	1082
AAG CTG TGA ACA CAT GGT GTA TAA ATT CTT TAC CAA GGC AAC TCA ACA CCT TCT					
1091	1100	1109	1118	1127	1136
TTC TCT GGG CTT GAA CCG CCA CTG CTC ACG TGG GCT TTA CAT ACA TTG ACC TTC					
1145	1154	1163	1172	1181	1190
CAT TCA CTG CAG TGG GAA TTC TCA GTG TGC AGA GGG AGA GGT TTT CTA GTC TGC					
1199	1208	1217	1226	1235	1244
AAA CTG AAA CAG TGT AAG AAG AAT AAA GTC TAT GAC TTT TAA ATA AAA AAA AAA 3'					

FIGURE 1C

25	L	D	R	D	V	A	R	A	I	E	L	L	E	K	L	Q	E	S	G	E	V	P	V	H	K	L	Q	S	L	K	1974337
117	L	E	R	D	V	Q	R	I	L	E	L	M	E	H	V	Q	K	T	G	E	V	N	N	A	K	L	A	S	L	Q	GI 1685067
55	K	V	L	Q	S	E	F	C	T	A	I	R	E	V	Y	Q	Y	M	H	E	T	I	T	V	N	G	C	P	E	F	1974337
147	Q	V	L	Q	S	E	F	F	G	A	V	R	E	V	Y	E	T	V	Y	E	S	I	D	A	D	T	T	P	E	I	GI 1685067
85	R	A	R	A	T	A	K	A	T	V	A	A	F	A	A	S	E	G	H	S	H	P	R	V	V	E	L	P	K	T	1974337
177	K	A	A	T	A	K	A	T	V	A	A	F	A	A	A	E	G	H	A	H	P	R	I	V	E	L	P	K	T	GI 1685067	
115	D	E	G	L	G	F	N	V	M	G	G	K	E	Q	N	S	P	I	Y	I	S	R	I	I	P	G	G	V	A	E	1974337
207	D	Q	G	L	G	F	N	V	M	G	G	K	E	Q	N	S	P	I	Y	I	S	R	I	I	P	G	G	V	A	D	GI 1685067
145	R	H	G	G	L	K	R	G	D	Q	L	L	S	V	N	G	V	S	V	E	G	E	H	H	E	K	A	V	E	L	1974337
237	R	H	G	G	L	K	R	G	D	Q	L	I	A	V	N	G	-	N	V	E	A	E	C	H	E	K	A	V	D	L	GI 1685067
175	L	K	A	A	K	D	S	V	K	L	V	V	R	Y	T	P	K	V	L	E	E	M	E	A	R	F	E	K	L	R	1974337
266	L	K	S	A	V	G	S	V	K	L	V	I	R	Y	M	P	K	L	L	D	E	M	E	R	R	F	E	R	Q	R	GI 1685067

FIGURE 2

## SEQUENCE LISTING

&lt;110&gt; INCYTE PHARMACEUTICALS, INC.

YUE, Henry

AU-YOUNG, Janice

PATTERSON, Chandra

&lt;120&gt; CELL JUNCTION PDZ PROTEIN

&lt;130&gt; PF-0599 PCT

&lt;140&gt; To Be Assigned

&lt;141&gt; Herewith

&lt;150&gt; 09/151,611

&lt;151&gt; 1998-09-11

&lt;160&gt; 3

&lt;170&gt; PERL Program

&lt;210&gt; 1

&lt;211&gt; 233

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte ID No: 1974337CD1

&lt;400&gt; 1

Met	Leu	Lys	Pro	Ser	Val	Thr	Ser	Ala	Pro	Thr	Ala	Asp	Met	Ala	
1				5					10					15	
Thr	Leu	Thr	Val	Val	Gln	Pro	Leu	Thr	Leu	Asp	Arg	Asp	Val	Ala	
			20						25					30	
Arg	Ala	Ile	Glu	Leu	Leu	Glu	Lys	Leu	Gln	Glu	Ser	Gly	Glu	Val	
			35						40					45	
Pro	Val	His	Lys	Leu	Gln	Ser	Leu	Lys	Lys	Val	Leu	Gln	Ser	Glu	
			50						55					60	
Phe	Cys	Thr	Ala	Ile	Arg	Glu	Val	Tyr	Gln	Tyr	Met	His	Glu	Thr	
			65						70					75	
Ile	Thr	Val	Asn	Gly	Cys	Pro	Glu	Phe	Arg	Ala	Arg	Ala	Thr	Ala	
			80						85					90	
Lys	Ala	Thr	Val	Ala	Ala	Phe	Ala	Ala	Ser	Glu	Gly	His	Ser	His	
			95						100					105	
Pro	Arg	Val	Val	Glu	Leu	Pro	Lys	Thr	Asp	Glu	Gly	Leu	Gly	Phe	
			110						115					120	
Asn	Val	Met	Gly	Gly	Lys	Glu	Gln	Asn	Ser	Pro	Ile	Tyr	Ile	Ser	
			125						130					135	
Arg	Ile	Ile	Pro	Gly	Gly	Val	Ala	Glu	Arg	His	Gly	Gly	Leu	Lys	
			140						145					150	
Arg	Gly	Asp	Gln	Leu	Leu	Ser	Val	Asn	Gly	Val	Ser	Val	Glu	Gly	
			155						160					165	
Glu	His	His	Glu	Lys	Ala	Val	Glu	Leu	Leu	Lys	Ala	Ala	Lys	Asp	
			170						175					180	

Ser Val Lys Leu Val Val Arg Tyr Thr Pro Lys Val Leu Glu Glu  
 185 190 195  
 Met Glu Ala Arg Phe Glu Lys Leu Arg Thr Ala Arg Arg Arg Gln  
 200 205 210  
 Gln Gln Gln Leu Leu Ile Gln Gln Gln Gln Gln Gln Gln Gln  
 215 220 225  
 Gln Thr Gln Gln Asn His Met Ser  
 230

<210> 2

<211> 1396

<212> DNA

<213> Homo sapiens

<220>

<221> misc\_feature

<223> Incyte ID No: 1974337CB1

<400> 2

cacgcacccg catgcacaca cgtatattct gaccatttta ttagagtgga aagttgaaag 60  
 gaagcaaccc gccagctaca cccaccacgc gctcctgggg gtggaatagc aaagttctag 120  
 ggcagagcct tccctcccag agcccggcga tgcagtcgct ctcggaatcc tgctcagctc 180  
 cgcaccgcaa ctgaagatct gccgcgcggg aacagttgcy tctccatctg gctaccaacc 240  
 cacccaagct ttcttctcca ccaccaccac ctctcttctt tccccctcct cccctctctt 300  
 tcggctctcc ctctccaccc ccgcccccaa tctctctctt tttttctcac tacgagcggt 360  
 tgctgatgct gaagccgagc gtcacttcgg ctcccacggc agacatggcg acattgacag 420  
 tggctccagcc gctcaccctg gacagagatg ttgcaagagc aattgaatta ctggaaaaac 480  
 tacaggaatc tggagaagta ccagtgcaca agctacaatc cctcaaaaaa gtgcttcaga 540  
 gtgagttttg tacagctatt cgagaggtgt atcaatatat gcatgaaacg ataactgtta 600  
 atggctgtcc cgaattccgt gcgagggcaa cagcaaaggc aacagttgca gcttttgcag 660  
 ctagtgaagg ccactcccac cctcgagtag ttgaactgcc aaagactgat gaaggccttg 720  
 gttttaatgt gatgggagga aaggagcaaa attcccccat ttatatctct cgcataattc 780  
 ctggaggggt ggctgaaaga cacggaggcc tcaaaagagg agaccagctg ctatcagtga 840  
 acggagtgtg tgtggaagga gaacaccatg agaaagctgt ggaactactc aaggctgcta 900  
 aagacagcgt caagctggtg gtgcgataca ccccaaaagt tctggaagaa atggaggctc 960  
 gctttgaaaa gctacgaaca gccaggcgct gccagcagca gcaattgcta attcagcagc 1020  
 agcaacagca gcagcagcaa caaacacaac aaaaccacat gtcataggcc cttgagggaa 1080  
 agctacttga tcaaacatcc gatagtcaca aatttgaaac cgtgcttcag aatcccagca 1140  
 catagtaaaa gacaacactg ataattatac ctgtcaagaa gctgtgaaca catggtgtat 1200  
 aaattcttta ccaaggcaac tcaacacctt ctttctcttg gcttgaaccg ccaactgctca 1260  
 cgtgggcttt acatacattg accttcatt cactgcagtg ggaattctca gtgtgcagag 1320  
 ggagagggtt tctagtctgc aaactgaaac agtgtaagaa gaataaagtc tatgactttt 1380  
 aaataaaaaa aaaaaa 1396

<210> 3

<211> 297

<212> PRT

<213> Caenorhabditis elegans

<300>

<308> GenBank ID No: g1685067

&lt;400&gt; 3

Met	Gly	Leu	Lys	Gly	Phe	Thr	Gly	Ser	Phe	Gln	Gln	Ile	Arg	Gly	
1				5					10					15	
Leu	Leu	Arg	Pro	Pro	Lys	Asn	Leu	Pro	Phe	Arg	Gly	Ile	Phe	Arg	
				20					25					30	
Lys	Asp	Gly	Glu	Val	Val	Arg	Lys	Asp	Asp	Leu	Leu	Val	Asn	Gln	
				35					40					45	
Phe	Lys	Met	Asn	Tyr	His	Pro	Gly	Leu	Asn	Val	Tyr	Tyr	Glu	Asn	
				50					55					60	
Asp	Arg	Gly	Glu	Arg	Leu	Leu	Arg	Ala	His	Cys	Asp	Gly	Ile	Val	
				65					70					75	
Arg	Ile	Ser	Gln	Glu	Lys	Cys	Asp	Pro	Asp	Tyr	Glu	Ile	Glu	Glu	
				80					85					90	
Met	Lys	Gly	Tyr	Glu	Tyr	Arg	Lys	Asp	Val	Asp	Leu	Tyr	Lys	Met	
				95					100					105	
Thr	Phe	Asn	Met	Asp	Asn	Pro	Asp	Gly	Pro	Asn	Leu	Glu	Arg	Asp	
				110					115					120	
Val	Gln	Arg	Ile	Leu	Glu	Leu	Met	Glu	His	Val	Gln	Lys	Thr	Gly	
				125					130					135	
Glu	Val	Asn	Asn	Ala	Lys	Leu	Ala	Ser	Leu	Gln	Gln	Val	Leu	Gln	
				140					145					150	
Ser	Glu	Phe	Phe	Gly	Ala	Val	Arg	Glu	Val	Tyr	Glu	Thr	Val	Tyr	
				155					160					165	
Glu	Ser	Ile	Asp	Ala	Asp	Thr	Thr	Pro	Glu	Ile	Lys	Ala	Ala	Ala	
				170					175					180	
Thr	Ala	Lys	Ala	Thr	Val	Ala	Ala	Phe	Ala	Ala	Ala	Glu	Gly	His	
				185					190					195	
Ala	His	Pro	Arg	Ile	Val	Glu	Leu	Pro	Lys	Thr	Asp	Gln	Gly	Leu	
				200					205					210	
Gly	Phe	Asn	Val	Met	Gly	Gly	Lys	Glu	Gln	Asn	Ser	Pro	Ile	Tyr	
				215					220					225	
Ile	Ser	Arg	Ile	Ile	Pro	Gly	Gly	Val	Ala	Asp	Arg	His	Gly	Gly	
				230					235					240	
Leu	Lys	Arg	Gly	Asp	Gln	Leu	Ile	Ala	Val	Asn	Gly	Asn	Val	Glu	
				245					250					255	
Ala	Glu	Cys	His	Glu	Lys	Ala	Val	Asp	Leu	Leu	Lys	Ser	Ala	Val	
				260					265					270	
Gly	Ser	Val	Lys	Leu	Val	Ile	Arg	Tyr	Met	Pro	Lys	Leu	Leu	Asp	
				275					280					285	
Glu	Met	Glu	Arg	Arg	Phe	Glu	Arg	Gln	Arg	Ile	Pro				
				290					295						

# INTERNATIONAL SEARCH REPORT

Int. doc. Application No.  
PCT/US 99/20988

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N15/12 C07K14/47 C12N15/63 C07K16/18 A61K38/17  
C12Q1/68

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N C07K A61K C12Q

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DATABASE GENEMBL 'Online! 15 November 1997 (1997-11-15) ROUSSET ET AL: "Homo sapiens Tax interaction protein 33 mRNA, partial cds." XP002126920 Accession AF028826	1-16,19
X	-& ROUSSET ET AL: "The C-terminus of the HTLV-1 Tax oncoprotein mediates interaction with the PDZ domain of cellular proteins" ONCOGENE, vol. 16, no. 5, 5 February 1998 (1998-02-05), pages 643-654, XP000865909 ----- -/--	1-16,19

☒ Further documents are listed in the continuation of box C.

☐ Patent family members are listed in annex.

### \* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

13 January 2000

Date of mailing of the international search report

26/01/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.  
Fax: (+31-70) 340-3016

Authorized officer

ALCONADA RODRIG..., A

# INTERNATIONAL SEARCH REPORT

Int. Patent Application No.  
PCT/US 99/20988

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>DATABASE TREMBL 'Online! 1 January 1998 (1998-01-01) BUTZ ET AL.: "VELI 1 (Tax interaction protein 33) fragment" XP002126919 Accession No. 014910</p>	1-16,19
P,X	<p>-&amp; BUTZ ET AL.: "A tripartite protein complex with the potential to couple synaptic vesicle exocytosis to cell adhesion in the brain" CELL, vol. 94, no. 6, 18 September 1998 (1998-09-18), pages 773-782, XP002126922</p>	1-16,19
P,X	<p>DATABASE GENEMBL 'Online! 11 August 1999 (1999-08-11) JO,K. AND BREDT,D.S.: "Homo sapiens LIN-7 homolog 1 (MALS-1) mRNA, complete cds." XP002126921 Accession AF173081</p>	1-16,19
P,X	<p>-&amp; JO, K. ET AL: "Characterization of MALS/Velis-1,-2, and -3: a family of mammalian LIN-7 homologs enriched at brain synapses in association with the postsynaptic density-95/NMDA receptor postsynaptic complex" JOURNAL OF NEUROSCIENCE, vol. 19, no. 11, 1 June 1999 (1999-06-01), pages 4189-4199, XP000865899 the whole document</p>	1-16,19

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 99/20988

## Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
Remark: Although claim 19  
is directed to a method of treatment of the human/animal  
body, the search has been carried out and based on the alleged  
effects of the compound/composition.
2. ☒ Claims Nos.: 17,18,20  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such  
an extent that no meaningful International Search can be carried out, specifically:  
See FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all  
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment  
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report  
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is  
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.



## INTERNATIONAL SEARCH REPORT

International Application No. PCT/US 99 20988

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 17,18,20

Claims 17 and 18 refer to an agonist and to an antagonist/inhibitor, respectively, of the polypeptide and claim 20 to a method of treatment of a subject with the antagonists of claim 18, without giving a true technical characterization. Moreover, no such compounds are defined in the application. In consequence, the scope of said claims is ambiguous and vague, and their subject-matter is not sufficiently disclosed and supported (Art. 5 and 6 PCT).

No search could be carried out for such purely speculative claims whose wording is, in fact, a mere recitation of the result to be achieved.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.